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ABSTRACT
The induction of type I interferon (IFN) and subsequent activation of interferon stimulated genes
(ISGs) represent a first line of defense against viral infection. Typically type I IFN signaling
leads to the phosphorylation of the STAT1 and STAT2 transcription factors (TFs) which then
form a trimetric complex with IRF-9 and translocate to the nucleus to induce ISG expression.
However, the results of this study showed that IFN-mediated upregulation of the ISG Oas1b, the
product of which confers resistance to flavivirus induced disease, can be induced in a STAT1independent manner. Since numerous ISGs have antiviral functions, many viruses have evolved
strategies to disrupt the type I IFN-signaling pathway. In cases when STAT1 activation is
blocked by a viral infection, STAT1-independent upregulation of ISGs provides an additional
strategy for the cell to mount an effective antiviral response. Infection of mouse
embryofibroblasts (MEFs) with West Nile virus (WNV) induced the production of IFN beta and
STAT1 and STAT2 phosphorylation but blocked nuclear translocation and binding of these TFs
to the promoters of the ISGs, Oas1a, Oas1a, Irf7 and Irf1. However, each of these antiviral ISGs
was efficiently upregulated in infected cells and IRF-9 was shown to be crucial for the

upregulation of Oas1a, Oas1b and Irf-7. IRF-3 or IRF-7 was needed to maintain the upregulation
of these genes at later times of infection. In contrast, the upregulation of Irf1 by WNV infection
did not depend on the tested IRFs but was reduced by inhibition of the p38 or NF-kappa B
pathways. Although Irf1 mRNA was efficiently upregulated in WNV-infected cells IRF-1
protein synthesis was blocked. The precise mechanism of the IRF-1 translational suppression is
not yet known, but the suppression was shown not to be due to increased proteasomal
degradation of IRF-1 nor to alternative splicing of Irf1 mRNA. Preliminary results suggest
miRNAs may play an indirect role in regulating IRF-1 translation.
The results of this study expand knowledge about the strategies evolved by viruses to evade host
cell antiviral responses and also provide valuable insights about alternative mechanisms utilized
by the host cell to counteract viral infections.

INDEX WORDS: West Nile virus, Type I IFN, ISG, 2'-5' Oligoadenylate synthetase, Oas1a,
Oas1b, Irf1, Irf7, Translational suppression
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CHAPTER 1
1
1.1

INTRODUCTION
Classification and medical importance of flaviviruses

The genus Flavivirus in the family Flaviviridae contains over 70 viruses including several
human pathogens such as dengue, Japanese encephalitis virus (JEV), yellow fever virus (YFV),
West Nile virus (WNV), St. Louis encephalitis virus (SLEV), Murray Valley encephalitis virus
(MVEV) and tick-borne encephalitis virus (TBEV). Many flaviviruses are transmitted by
arthropods and cause a variety of diseases including fever, encephalitis, meningitis and
hemorrhagic fever (Lindenbach, 2007). A secondary Dengue infection with a different serotype
can lead to a life threatening hemorrhagic fever with a mortality rate of about 5%. Vaccines are
available for only a few flaviviruses, namely YFV, TBEV and JEV. WNV is transmitted in
nature via a mosquito-bird cycle. Although WNV primarily infects birds, it occasionally infects
mammals including humans and horses. The majority of WNV infections in humans are
asymptomatic; however, infection induces a mild febrile illness in about 20% of infected
individuals and encephalitis or poliomyelitis-like disease in less than 1% of infected individuals
(Petersen et al., 2003). WNV isolates have been divided into two lineages. Lineage I strains are
often associated with outbreaks of human disease, while the majority of lineage II strains are
non-emerging and cause zoonotic infections in Africa (Brinton, 2002). No antiviral therapies or
human vaccines have been developed so far to treat or prevent WNV infections.
1.2

General characteristics of WNV.

The WN virion is spherical and has a diameter of 40-60 nm. It contains a positive sense, single
stranded RNA genome of about 11,000 nucleotides. Similar to cellular mRNAs, the viral genome
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is capped at the 5' end; however, it lacks a poly A at the 3' end. The single open reading frame
of WNV genome encodes a polyprotein that when processed by viral and cell proteases produces
ten mature viral proteins (Fig. 1.1). Viral structural proteins [capsid (C), membrane (prM/M) and
the envelope (E)] are encoded by the 5' portion of the genome open reading frame (ORF) and the
nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) are encoded by the 3’
portion. The genome is surrounded by a capsid layer composed of dimers of the C protein. A
host-derived lipid envelope surrounds the capsid layer and is spanned by the transmembrane
regions of viral E and M proteins (Lindenbach, 2007).
1.3

Flavivirus replication cycle.

The flavivirus E protein binds to an unknown receptor(s) on the cell surface and this leads to
clathrin-mediated endocytosis (Fig. 1.2). Upon acidification of the virion-containing endocytic
vesicle, the E protein undergoes a low pH mediated conformational change that leads to the
fusion of the viral envelope with the late endosome (Chu and Ng, 2004). The viral genome is
released into the cytoplasm and is translated into a single polyprotein that is then processed by
viral and cellular proteases to produce the mature viral proteins (Lindenbach, 2007). Viral
replication occurs entirely in the cytoplasm of the infected cell. The replication of flavivirus
RNA is associated with extensive membrane biogenesis and rearrangements and viral RNA
replication complexes are formed in invaginations of the endoplasmic reticulum (ER). Each of
these endoplasmic vesicles is connected with the cytoplasm via a narrow “neck” (Gillespie et al.,
2010). Accumulation of viral nonstructural proteins including the NS5 RNA dependent RNA
polymerase, results in the synthesis of negative sense RNA which in turn functions as a template
for the synthesis of genomic plus strand RNA (Lindenbach, 2007). Initially the synthesis of
minus and plus RNA is symmetric; however, about 6-10 h after infection, synthesis becomes
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asymmetric with about 10 to 100 times more plus strand synthesis occurring (Chu and
Westaway, 1985). The newly synthesized genomic RNA moves through the neck of the vesicles
into the cytoplasm where it either associates with ribosomes and is translated or associates with
capsid proteins associated with ER membranes that also contain E and M proteins and buds into
the lumen of the ER forming immature virions (Gillespie et al., 2010). Immature virions are then
transported through the trans-Golgi to the plasma membrane. During transport, prM is cleaved
by the Golgi-resident protease furin into pr and M. As a result the prM-E complexes dissociate
allowing the formation of E protein homodimers and maturation to “smooth surface” viral
particles (Stadler et al., 1997). Mature virions are released from infected cells by the fusion of
the virus-containing vesicle with the cell plasma membrane (Mackenzie and Westaway, 2001).
1.4

Host cell response to viral infection.

Viral infection is sensed through pattern recognition receptors (PRR) that recognize specific
pathogen-associated molecular patterns (PAMPs) within viral structures. PRRs that recognize
viral infections include Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs). The TLR
family includes twelve members that bind to a variety of PAMPs (Akira, 2009). Viral ribonucleic
acids are recognized by three of the TLRs. TLR-3 is expressed at the cell surface or in
endosomes (Matsumoto et al., 2003) and recognizes double stranded dsRNA (dsRNA)
(Alexopoulou et al., 2001). Upon binding dsRNA, TLR-3 binds the TIR domain containing
adaptor-inducing IFN beta (TRIF) adaptor molecule and activates the IRF-3, NF-kappa B and
ATF2/c-Jun (AP1) transcription factors (TFs) which activate IFN beta expression (Akira, 2009).
TLR-7 and TLR-8 recognize single stranded RNAs (ssRNAs) (Diebold et al., 2004; Heil et al.,
2004; Triantafilou et al., 2005) and signal through the adaptor molecule myeloid differentiation
factor 88 (MyD88) to activate IRF-7 and NF-kappa B and induce type I IFN expression (Akira,
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2009). The involvement of TLR-3 in the antiviral response of mice to WNV infection is not
clear. Although a previous study reported that blood-barrier permeability and WNV entry into
the brain was decreased in TLR-3-/- mice, suggesting that TLR-3 promotes WNV entry into the
brain (Wang et al., 2004), a second study showed that TLR-3 plays a protective role against
WNV infection by restricting virus replication in neurons (Daffis et al., 2008). TLR-7 was
reported to be important in promoting effective WNV clearance in mice (Town et al., 2009;
Welte et al., 2009).
Viral RNA structures can also be detected by retinoic acid inducible gene-I (RIG-I) and
melanoma differentiation antigen 5 (MDA5). These cytoplasmic sensors are DExD/H helicases
containing two caspase activation and recruitment domains (CARDs) at their N termini.
Although the RIG-I like receptors share about 25% identity within the CARD domains and about
40% identity within the helicase domains (Barral et al., 2009), they recognize different RNA
species. RIG-I binds ssRNA molecules containing a 5' triphosphate, short dsRNAs, and
adenosine/uridine rich RNAs while MDA5 has been shown to be activated by long dsRNAs
(Hornung et al., 2006; Marques et al., 2006; Kato et al., 2008; Saito et al., 2008; Takahasi et al.,
2008). Activated RIG-I and MDA5 bind the IFN beta promoter stimulator (IPS)-1 protein that
serves as a downstream adaptor molecule. IPS-1 then induces downstream signaling cascades
leading to the activation of TFs mediating upregulation of IFN (Barral et al., 2009). Recent
studies suggest that both RIG-I and MDA5 play a role in sensing WNV infection and the
induction of IFN (Fredericksen et al., 2008; Loo et al., 2008). The IFN response to WNV
infection was completely abolished in cells lacking IPS-1 (Fredericksen et al., 2008) confirming
the importance of the RLRs and IPS-1 signaling in the response to WNV infection.
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1.5

IFN system

IFNs are secreted cytokines that play a pivotal role in host defense against intracellular
pathogens. IFNs can directly inhibit a virus infection by the induction of IFN stimulated genes,
(ISGs) many of which have antiviral functions, or indirectly through the induction of major
histocompatibility complex (MHC) antigens and the activation of immune cells (Paun and Pitha,
2007). IFNs are grouped into three classes based on their amino acid sequence and recognition
by specific receptors. Type I IFNs consist of IFN- alpha (α), -beta () and the lesser known IFNs,
-omega (), -epsilon (), -kappa (), - delta (), -tau () and – zeta (). Only IFN alpha, beta,
omega, epsilon and kappa are found in humans. IFN alpha and beta are secreted by a wide
variety of cells including macrophages, lymphocytes, fibroblasts, endothelial cells, osteoblasts
and others (Pestka et al., 2004) while the other type I IFNs are expressed in specific cell types
(Table 1.1). IFN alpha and IFN-beta have been extensively studied and were shown to play a
major role in the innate response to viral infections (Randall and Goodbourn, 2008). Since IFNalpha and IFN-beta are secreted by fibroblasts, this dissertation will concentrate on these two
subtypes of type I IFNs. The type II IFN class consists of only IFN-gamma (γ), which is critical
for both the innate and adaptive immune responses to virus infection, intracellular bacterial
infections as well as tumor control. IFN-gamma is produced by macrophages, natural killer cells
(NK) and by CD4 and CD8 cytotoxic T-cells (Takaoka and Yanai, 2006; Schoenborn and
Wilson, 2007). Type III IFNs consist of IFN-lambda 1 (1), -lambda 2 (2) and –lambda 3 (3)
which are also referred to as IL-29, IL-28A and IL-28B, respectively. These IFNs are closely
related to type I IFNs (Li et al., 2009).
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Table 1.1. Classification of IFNs, subtypes, their receptors and expression patterns.
Class

Subtype

Receptor subunits

Transcription
factors induced

DNA
binding
site

Expression

I

IFN-α

IFNAR1/IFNAR2

ISGF3*

ISRE

Ubiquitous

IFN-

IFNAR1/IFNAR2

ISGF3

ISRE

Ubiquitous

IFN-

IFNAR1/IFNAR2

ISGF3

ISRE

Trophoblasts

IFN-

IFNAR1/IFNAR2

ISGF3

ISRE

Uterus, Ovary

IFN-

IFNAR1/IFNAR2

ISGF3

ISRE

Leukocytes

IFN-

IFNAR1/IFNAR2

ISGF3

ISRE

Epidermal keratinocytes

IFN-

IFNAR1/IFNAR2

ISGF3

ISRE

Trophoblasts

IFN-

IFNAR1/IFNAR2

ISGF3

ISRE

Spleen, thymus, lymph
node

II

IFN-

IFNGR1/IFNGR2

GAF**

GAS

Macrophage, T cell, NK
cell

III

IFN-1

IFNLR1/IL10R2

ISGF3

ISRE

Ubiquitous

IFN-2

IFNLR1/IL10R2

ISGF3

ISRE

Ubiquitous

IFN-3

IFNLR1/IL10R2

ISGF3

ISRE

Ubiquitous

*

ISGF3 (STAT1, STAT2 and IRF9)
GAF (STAT1 homodimer)
Compiled from reviews (Takaoka and Yanai, 2006; de Weerd et al., 2007; Fensterl and Sen, 2009).
**
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1.6

Type I IFN signaling pathway.

During a viral infection, activation of a PRR leads to the induction of signaling pathways
resulting in the activation of TFs including IRF-3, NF-kappa B and AP1 which translocate to the
nucleus and cooperatively activate IFN-beta gene expression (Barral et al., 2009). Secreted IFN
beta binds to a cellular receptor complex composed of two subunits, IFNAR1 and IFNAR2 (Fig.
1.3), that are associated with Janus kinases (JAKs). The cytoplasmic tail of IFNAR1 is
associated with the tyrosine kinase (Tyk2) while the cytoplasmic tail of IFNAR2 is associated
with Jak1. The binding of IFN to the receptor complex induces cross-activation of these kinases.
IFNAR1 is then phosphorylated by Tyk2 which allows recruitment of signal transducer and
activator of transcription 2 (STAT2) to the receptor and its phosphorylation by Tyk2. Next
STAT1 binds to STAT2 and is phopshorylated by Jak1. Phosphorylated STAT1 and STAT2
form a trimeric transcription factor complex referred to as IFN stimulated gene factor 3 (ISGF3)
with IFN regulatory factor-9 (IRF-9). This complex translocates to the nucleus and binds to IFN
stimulated response elements (ISREs) in the promoters of ISGs (Paun and Pitha, 2007; Randall
and Goodbourn, 2008). One of the ISGs induced by IFN-beta is IRF-7. It is a transcription factor
involved in the induction of the IFN-alpha genes. In addition IRF-7 forms a complex with IRF-3
that binds to the IFN-beta promoter and induces its expression (Wathelet et al., 1998). Secreted
IFN-alpha utilizes the same signaling pathway as IFN beta resulting in the amplification of the
type I IFN response via a positive feedback loop (Marie et al., 1998; Sato et al., 2000).
1.7

Type II IFN and type III IFN signaling pathways.

In the case of type II IFN signaling, IFN-gamma binds to the IFNGR1 and IFNGR2 receptor
complex which leads to the formation of a STAT1 homodimer that is referred to as IFN-alpha
factor (GAF). This complex translocates to the nucleus and binds to IFN-gamma activated
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Figure 1.3. Type I IFN induction in MEFs in response to viral dsRNA signaling in MEFs.
The binding of viral dsRNA to endoplasmic and/or cytoplasmic sensors leads to the activation of
TFs required for IFN beta expression. Secreted IFN beta binds to the cellular receptor and
activates the JAK-STAT signaling pathway that leads to upregulation of ISGs including Irf7. The
IRF-7 TF activates the expression of IFN alpha genes and enhances upregulation of the IFN beta
gene.
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sequences (GAS) in the promoters of IFN-gamma responsive genes. Although IFN-gamma
primarily activates the GAF complex, it can also activate the formation of the ISGF3 complex.
Likewise IFN-alpha/beta signaling mainly activates the formation of ISGF3 but can also activate
GAF (Kessler et al., 1990; Decker et al., 1991; Lew et al., 1991; Williams, 1991). Type III IFNs
bind to a receptor complex composed of a specific receptor subunit IFNLR1and IL10R2. Similar
to the type I IFN signaling pathway, the induction of IFN-lambda leads to the formation of the
ISGF3 complex (Kotenko et al., 2003). However, the mechanism of IFN-lambda downstream
signaling remains to be elucidated in detail.
1.8

Interferon regulatory factor family.

ISGs are typically induced by type I IFN through the binding of ISGF3 to ISREs with a
consensus sequence 5' A/GNGAAANNGAAACT 3' located in the promoters of ISGs (Darnell et
al., 1994). However, increasing evidence shows that some ISGs can be upregulated by viral
infections in an IFN-independent manner. Besides ISGF3, additional complexes: ISGF1 (IRF-2)
and ISGF2 (IRF-1) were identified to bind an ISRE (Kessler et al., 1988; Levy et al., 1988). The
mammalian IRF family comprises of nine members, IRF-1 through IRF-9 (Table 1.2). Each of
these proteins has a conserved DNA binding domain, and is a transcription factor and can bind to
IRF-E binding sites in the promoters of some genes. The sequences of IRF-E sites are similar to
that of the ISRE and contain tandem repeats of GAAA motifs separated by two bases (Honda
and Taniguchi, 2006).

IRF-1 is a very unstable protein with a half-life of about 30 m (Watanabe et al., 1991). It is
usually undetectable or expressed at low levels in a variety of cell types; however, it can be
upregulated by some viral infections, type I or II IFNs or TNF. Activation of IRF-1 is
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Table 1.2. Comparison of IRF family members.
Factor

Expression pattern

Role in host defense

IRF-1

Ubiquitous

Type I IFN and ISG induction

IRF-2

Ubiquitous

Repression or induction of ISGs

IRF-3

Ubiquitous

Type I IFN and ISG induction

IRF-4

Hematopoietic cells

Immune cell differentiation and cytokine expression

IRF-5

Ubiquitous

Type I IFN and cytokine induction

IRF-6

High in skin cells

Unknown

IRF-7

Ubiquitous

Type I IFN and ISG induction

IRF-8

Hematopoietic cells

Cell differentiation and cytokine expression

IRF-9

Ubiquitous

ISG induction

Modified from (Ozato et al., 2007).
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controlled by phosphorylation (Taniguchi et al., 2001). IRF-1 can also be SUMOylated, which
was shown to increase its stability, or ubiquitylated, which leads to its degradation by the
proteasome (Park et al., 2007). Although, IRF-1 was initially described as a transcriptional
activator of IFN-beta expression (Miyamoto et al., 1988); subsequently, it was also shown to
upregulate some ISGs in an IFN-independent manner (Schoggins et al., 2011). One of the IRF-1
target genes, viperin (Stirnweiss et al., 2010) was reported to inhibit both WNV and dengue
infections (Jiang et al., 2010). In addition, a recent study showed that overexpression of IRF-1
leads to the inhibition of the replication of not only WNV and other flaviviruses such as dengue
virus, YFV, and hepatitis C virus, but also other types of viruses including Chikungunya virus,
Venezuelan encephalitis virus and human immunodeficiency virus 1 (HIV) (Schoggins et al.,
2011). In addition to the induction of antiviral genes, IRF-1 also activates the expression of
genes regulating innate and adaptive immune responses, the cell cycle, apoptosis, DNA damage
repairs and tumor-suppression (Taniguchi et al., 2001). Because IRF-1 functions as a tumor
suppressor, its expression is suppressed in many tumor cells to prevent apoptosis and cell cycle
arrest from occurring (Taniguchi et al., 1997). MEFs and hepatocytes lacking IRF-1 were unable
to undergo growth arrest. In addition, IRF-1 together with p53 was required for optimal
induction of the cyclin-dependent kinase inhibitor p21 after treatment with ionizing radiation
(Tanaka et al., 1996).

In contrast to IRF-1, IRF-2 is a relatively stable protein (half-life of about 8 h) (Watanabe et al.,
1991) and it was shown to function as a transcriptional repressor of the type I IFN gene and some
ISGs (Harada et al., 1989; Harada et al., 1990; Hida et al., 2000). However, additional studies
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showed that IRF-2 can also act as a transcriptional activator of some genes (Vaughan et al.,
1995; Jesse et al., 1998).

Similar to IRF-1, IRF-3 and IRF-7 are TFs that play distinct and nonredundant roles in the
induction of type I IFN (Sato et al., 2000). IRF-3 is a constitutively expressed protein that is
found in the cytoplasm of all cells in an inactive form. During a viral infection, it undergoes
phosphorylation which induces dimerization followed by translocation to the nucleus in a
complex with the histone acetyltransferases p300 and CREB-binding protein (CBP) (Yoneyama
et al., 1998; Suhara et al., 2002; Fitzgerald et al., 2003; Sharma et al., 2003). Although IRF-3
alone is not sufficient to induce IFN beta expression, it cooperates with NF-kappa B and AP1
TFs to enhance IFN beta expression. IRF-3 was also identified as a component of the virusinducible dsRNA-activated factor 1 complex (DRAF1) (Weaver et al., 1998) that was shown to
play a role in IFN-independent upregulation of a subset of ISGs (Grandvaux et al., 2002;
Andersen et al., 2008). In contrast to the constitutive expression of IRF-3, IRF-7 expression is
typically induced by type I IFN signaling. IRF-7 plays a role in the later phase of the type I IFN
response to viral infection through the amplification of the response via the activation of various
IFN-alpha species and IFN-alpha dependent genes (Marie et al., 1998; Sato et al., 1998) as well
as by enhancing IFN-beta production (Wathelet et al., 1998). Several ISGs can also be
upregulated directly by IRF-7 (Barnes et al., 2004).
IRF-4 and IRF-8 expression is restricted to particular types of immune cells. These IRFs play a
role in the regulation of cell differentiation, DNA repair and cytokine production (Ozato et al.,
2007).

IRF-5 is ubiquitously expressed and was shown to be involved in virus-mediated

activation of type I IFN and inflammatory cytokines (Barnes et al., 2001; Schoenemeyer et al.,
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2005; Takaoka et al., 2005; Paun et al., 2008). The role of IRF-6 in the immune response has not
been studied. IRF-6 is expressed to high levels in skin cells and is important for regulation of
skin cell development (Ozato et al., 2007).
IRF-9 plays a crucial role in type IFN-signaling and the activation of ISGs. It associates with
STAT1 and STAT2 to form the trimeric ISGF3 transcription factor complex that binds to ISREs
in the promoters of ISGs and activates their expression (Paun and Pitha, 2007) (Fig.1.3). One
previous study reported that although IRF-9 translocated to the nucleus, it could not activate
gene expression alone (Kraus et al., 2003). However, both a IRF-9/STAT2 complex and a IRF9/STAT2 fusion protein were shown to efficiently activate ISRE-driven transcription of a
reporter gene (Kraus et al., 2003; Lou et al., 2009) suggesting that IRF-9 may play a role in
ISGF3-independent gene expression when complexed with other factor(s).
1.9

Strategies utilized by viruses to evade host immune antiviral responses

The establishment of an antiviral state largely depends on both the induction of IFN and the
functions of antiviral ISGs and many viruses have evolved mechanisms to suppress the
expression of ISGs. Three main strategies utilized by viruses to suppress the induction of ISGs
are: inhibition of IFN production, inhibition of the IFN signaling pathway and blockage of the
synthesis of antiviral proteins. Within each of these strategies, different viruses have evolved
strain, cell type and species specific mechanisms to evade the induction of the antiviral state.
1.9.1 Inhibition of IFN production by viruses
Because IFN induction is a result of the recognition of viral structures by PRRs, many viruses
have developed replication strategies that minimize the production of PAMPs. For example,
flaviviruses replicate their RNA in endoplasmic perinuclear membrane vesicles (Mackenzie,
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2005; Welsch et al., 2009; Gillespie et al., 2010) that likely limit the detection of viral nucleic
acid structures during the exponential replication phase. A recent report showed that although
PKR, a dsRNA sensor, is not actively suppressed by WNV Eg101 infection, it is not activated in
infected rodent cells (Elbahesh et al., 2011). However, during the initial stages of WNV infection
when the replication complexes are not yet well formed the small amounts of RNA species
including dsRNA produced may be detected by PRR. RIG-I and MDA5 cytoplasmic sensors
were previously shown to mediate the activation of the IRF-3 (Fredericksen and Gale, 2006;
Scherbik et al., 2007; Fredericksen et al., 2008) and NF-kappa B (Scherbik, Pulit-Penaloza and
Brinton, unpublished data) TFs and the subsequent induction of type I IFN in WNV infected
cells.
Many viruses encode proteins that were experimentally shown to antagonize IFN induction by
binding dsRNA and limiting activation of host dsRNA binding sensors or by direct inhibition of
RIG-I, MDA-5 or TLR-3 signaling or by blocking the activation of IRF-3 or NF-kappa B TFs
[Reviewed in (Randall and Goodbourn, 2008)]. In the case of WNV, the NS2A protein of the
attenuated lineage I WNV strain, Kunjin was shown to inhibit IFN beta transcription by an
unknown mechanism (Liu et al., 2004; Liu et al., 2006).
1.9.2 Inhibition of IFN signaling by viruses
Numerous reports showed that viruses can block IFN signaling at virtually each step of that
pathway [reviewed in (Randall and Goodbourn, 2008)]. Some of the strategies reported for
different strains of WNV include downregulation of IFN alpha/beta R expression (Evans et al.,
2011), suppression of type I IFN signaling through the redistribution of cholesterol (Mackenzie
et al., 2007), blockage of JAK and Tyk phosphorylation (Guo et al., 2005) and blockage of
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STAT1 and STAT2 phosphorylation and translocation to the nucleus (Laurent-Rolle et al.; Liu et
al., 2005; Keller et al., 2006).
1.9.3 Mechanisms of blockage of the synthesis of antiviral proteins by viruses.
One of the strategies utilized by viruses to antagonize the host innate response to viral infection
is the inhibition of protein translation. The process of translation is divided into the initiation,
elongation, termination and ribosome recycling phases. Although viruses can inhibit translation
at each of these steps, most reports show that translation is mainly regulated at the level of
initiation (Walsh and Mohr, 2011). Induction of global inhibition of host mRNA translation is
beneficial for viruses that have evolved alternative translational mechanisms for viral protein
translation. For example, both caliciviruses, which encode proteins that serve as cap-analogues,
and picornaviruses, which can initiate translation from an internal ribosome entry site (IRES),
can initiate translation of viral proteins when cap-dependent translation is blocked (Lopez-Lastra
et al., 2010). However, many viruses including flaviviruses depend entirely on the canonical host
translation machinery and so are susceptible to global translation inhibition. Hence, inhibition of
host translation is not observed in flavivirus infected cells (Lindenbach, 2007).
An alternative means of inhibiting protein translation by viruses is blocking the export of cellular
mRNAs from the nucleus as has been observed for adenovirus, influenza virus and vesicular
stomatitis virus (VSV) infections (Faria et al., 2005; Satterly et al., 2007; Yatherajam et al.,
2011). Some herpesviruses have also been shown to suppress host protein translation through the
induction of increased cell mRNA turnover (Glaunsinger and Ganem, 2004; Feng et al., 2005;
Lee and Glaunsinger, 2009; Clyde and Glaunsinger, 2010).
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Several known mechanisms of transcript specific suppression of translation have been reported.
One of these involves the binding of host RNA binding proteins to cis-acting elements in the
3'UTRs of target mRNAs which inhibits translation initiation (Abaza and Gebauer, 2008). For
example, translational repression by trans-acting proteins binding to the 3'UTR was reported for
the 15-lipoxygenase (Ostareck et al., 1997), MEF-2A (Black et al., 1997) and p53 (Fu and
Benchimol, 1997) mRNAs. Proteins binding to AU-rich elements (AREs) in the 3'UTRs of target
mRNAs can cause either destabilization or stabilization mRNA or suppress translation (Zhang et
al., 2002). In rare instances, translation initiation can be blocked by the binding of a RNA
binding protein to a cis-element in the 5'UTR (Gray and Hentze, 1994). It is possible that a viral
infection may induce this type of transcript regulation of protein translation but no examples
have yet been reported.
Transcript specific protein synthesis can also be suppressed by specific micro RNAs (miRNAs).
RNA interference was first described as an antiviral mechanism in plants (Lindbo et al., 1993;
Ratcliff et al., 1997; Anandalakshmi et al., 1998; Brigneti et al., 1998; Kasschau and Carrington,
1998; Hamilton and Baulcombe, 1999). Hundreds of miRNAs have been identified in humans
with each of the miRNAs having the potential to regulate multiple genes (Bentwich, 2005).
Many miRNA genes are transcribed under strict developmental-stage and tissue-specific control.
Primary miRNA transcripts (pri-miRNAs) form stem-loop structures which are cleaved by the
RNase III enzyme drosha to precursor miRNAs (pre-miRNAs) that are transported from the
nucleus into the cytoplasm by exportin 5. In the cytoplasm, pre-miRNAs are cleaved by the
RNase III enzyme dicer into mature miRNAs (Murchison and Hannon, 2004). The guide strand
of a mature ~22 nucleotide miRNA associates with argonaute proteins and other components to
form miRNA-induced silencing complexes (miRISC). The miRNAs guide these complexes to
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Figure 1.4. miRNA maturation. Primary pri-miRNA is cleaved by Drosha in the nucleus. The
pre-miRNA is then transported into the cytoplasm where is cleaved into mature miRNA by dicer.
The miRNA guide strand then associates with argonaute proteins and other components of the
miRISC complex and targets a specific mRNA.
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the target mRNAs and the interaction of usually multiple miRNAs with a target RNAs leads to
translation suppression or inhibition or alteration of target mRNA stability (Eulalio et al., 2008;
Hutvagner and Simard, 2008). miRNAs most often bind to the 3'UTR of a target message.
Occasionally, miRNAs bind to 5'UTR or ORF regions but they are usually less effective in
silencing translation at these sites (Lytle et al., 2007). Additionally, it has been shown that the
binding of miRNAs can lead to sequestering target mRNAs in processing bodies (P-bodies)
(Parker and Sheth, 2007).
Some viruses including herpesviruses, adenoviruses and polyomaviruses encode miRNAs which
regulate viral and/or host cell gene translation (Gottwein and Cullen, 2008; Grundhoff and
Sullivan, 2011). Other viruses such as Epstein-Barr virus (Motsch et al., 2007; Cameron et al.,
2008; Ho et al., 2011) and enteroviruses (Ho et al., 2011) induce the expression of cellular
miRNAs that benefit the virus, while HIV infections downregulate cellular miRNAs that inhibit
viral replication (Triboulet et al., 2007). The majority of known viral miRNAs are encoded by
DNA viruses due to the fact that the maturation of miRNAs involves cleavage by drosha in the
nucleus (Rouha et al., 2010). However, a recent study showed that TBEV containing a EBV premiRNA in its genome can express mature miRNA in the cytoplasm without the involvement of
drosha processing (Rouha et al., 2010). Although none of the so far identified viral miRNAs are
encoded by RNA viruses which replicate in the cytoplasm this study indicates that the generation
of miRNAs by cytoplasmic viruses is mechanistically feasible. Interestingly, several flaviviruses
produce a highly structured, nuclease resistant, noncoding RNA derived from the 3' UTR of the
viral genome that was shown to be crucial for virus-induced cytopathicity and pathogenicity
(Pijlman et al., 2008). More recently the 3'UTR of the WNV strain Kunjin was reported to
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encode a miRNA-like small RNA that is important for efficient replication of this virus in
mosquito cells (Hussain et al., 2011).
GOALS OF THE DISSERATION
WNV-host cell interactions are not fully understood and the overall goal of this study is to
investigate mechanisms by which WNV modulates the expression of host antiviral genes.
Although WNV strains have the ability to inhibit IFN signaling, efficient upregulation of many
ISGs including Oas1a, Oas1b and Irf7 was still observed in cells infected with these viruses
(Fredericksen et al., 2004; Scherbik et al., 2006; Daffis et al., 2007; Scherbik et al., 2007; Daffis
et al., 2008; Fredericksen et al., 2008). Although it was previously reported that the expression of
some ISGs can be upregulated in an IFN-independent manner, many ISGs including Irf7, Oas1a
were thought to be activated only in a type I IFN-dependent-manner. In addition, our previous
results showed that the upregulation of a subset of ISGs including Irf1 is delayed in WNVinfected cells. Also protein expression of the delayed subset of ISGs was suppressed in WNV
Eg101-infected MEFs (Scherbik et al., 2007). The mechanisms of ISG transcription regulation in
IFN beta-treated and WNV Eg101-infected MEFs will be investigated under Aims 1 and 2, while
the mechanism of WNV Eg101 induced suppression of ISG protein levels will be analyzed under
Aim 3.
AIM 1. Functional analysis of the induction of Oas1a and Oas1b promoters by type I IFN.
AIM 2. Investigation of the activation of ISGs in MEFs infected with WNV Eg101.
AIM 3. Investigation of transcriptional and translational regulation of IRF-1 expression in
WNV Eg101-infected MEFs.
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CHAPTER 2

2

AIM 1: Functional analysis of the induction of Oas1a and Oas1b promoters by type I
IFN.
The data from this aim has been accepted for publication in Virology, 2012.

INTRODUCTION
The recognition of viral dsRNA by cellular sensors in infected cells leads to activation of the NFkappa B, IRF-3 and ATF2/c-Jun transcription factors that bind cooperatively to the interferon
(IFN) beta promoter and activate its transcription (Merika and Thanos, 2001). IFN beta secreted
by infected cells binds to IFN alpha/beta receptors on the surfaces of both infected and
uninfected cells resulting in activation of JAK1 and Tyk2 kinases that phosphorylate STAT1 and
STAT2 transcription factors. Phosphorylated STAT1 and STAT2 and IFN regulatory factor 9
(IRF-9) form the IFN stimulated gene factor 3 complex (ISGF3) that translocates to the nucleus
where it binds to IFN stimulated response elements (ISREs) in the promoters of IFN stimulated
genes (ISGs) and upregulates their expression (Stark et al., 1998).

Three oligoadenylate synthetase genes (OAS1, OAS2 and OAS3) and one OAS-like (OASL)
gene have been identified in the human genome (Hovnanian et al., 1998; Rebouillat et al., 1998).
The transcripts of three of these genes are alternatively spliced and polymorphisms have been
identified that alter splicing sites. Five isoforms have been reported for OAS1 (p42, p44, p46/p48
and p52), two for OAS2 (p69 and p71), one for OAS3 (p100) and two for OASL (p30 and p59)
(Hartmann et al., 1998; Rebouillat et al., 1998; Hovnanian et al., 1999; Justesen et al., 2000;
Bonnevie-Nielsen et al., 2005). In contrast, the mouse genome contains eight OAS1 (Oas1a-
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Oas1h), two OASL (Oasl1 and Oasl2), one OAS2 (Oas2) and one OAS3 (Oas3) gene orthologs
(Rutherford et al., 1991; Justesen et al., 2000; Shibata et al., 2001; Kakuta et al., 2002). Gene
duplication, rather than alternative splicing, is responsible for the multiple murine Oas1 isoforms
(Perelygin et al., 2006). Enzymatically active OAS proteins play an important antiviral role.
When activated by viral dsRNA, they catalyze the synthesis of short 2'-5'-oligoadenylates (2-5A)
from ATP. 2-5A activates latent endonuclease RNase L which degrades both cellular and viral
single-stranded RNAs (Samuel, 2001). Among the eight murine Oas1 proteins, only Oas1a and
Oas1g have been reported to be active 2'-5'-oligoadenylate synthetases (Kakuta et al., 2002;
Elbahesh et al., 2011). However, the inactive synthetase Oas1b mediates resistance to flavivirusinduced disease through an unknown mechanism that is independent of RNase L (Scherbik et al.,
2006). The flavivirus-induced disease resistant mouse strain C3H/RV is homozygous for the
dominant Oas1br allele encoding a full length Oas1b protein, while the congenic susceptible
mouse strain C3H/He is homozygous for the recessive Oas1bs allele that encodes a C-terminally
truncated Oas1btr protein (Perelygin et al., 2002). A previous study showed that the full length
Oas1b protein, which is an inactive synthetase, can inhibit in vitro Oas1a synthetase activity in a
dose-dependent manner and reduce 2-5A production in vivo in response to poly(I:C) (Elbahesh et
al., 2011). A similar function was reported for Oas1d, another of the inactive Oas1 proteins (Yan
et al., 2005).

Each of the human OAS genes contains an ISRE in its promoter and is induced by type I IFN
(Wang and Floyd-Smith, 1997; Hartmann et al., 1998; Floyd-Smith et al., 1999; Yu et al., 1999;
Rebouillat et al., 2000). Similarly, murine Oas gene expression with the exception of Oas1f was
reported to be activated by type I IFN (Eskildsen et al., 2002; Eskildsen et al., 2003). A previous
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TFSEARCH analysis predicted transcription factor binding sites (TFBSs) in 500 bp promoter
fragments of the murine Oas1a-h, Oas2 and Oas3 genes and identified an ISRE in only the
promoters of the Oas1a, Oas1b, Oas1g and Oas2 genes (Mashimo et al., 2003). Only the ISRE in
the Oas1b promoter was predicted to overlap GAS and NF-kappa B sites. These results
suggested the possibility of differential regulation of Oas1a and Oas1b expression by IFN and/or
viral infection but this prediction was not functionally tested.

In the present study, the Oas1a and Oas1b promoters from both C3H/RV and C3H/He mouse
embryofibroblasts (MEFs) were cloned and sequenced. A GENOMATIX search of the Oas1a
and Oas1b promoter sequences predicted that neither had a TATA box but that both had a
canonical initiator element (INR). An inverted CCAAT element (ICE) was predicted and
functional analysis showed that it may be important for the basal activities of the C3H/He and
C3H/RV Oas1b promoters and the C3H/RV Oas1a promoter. The C3H/He Oas1a promoter
contained a mutation in this site that was predicted to make it nonfunctional. A single ISRE as
well as overlapping STAT and IRF sites were predicted in both promoters. Functional mapping
of the Oas1a and Oas1b promoters by sequential 5' deletion and TFBS mutagenesis indicated
that the ISRE as well as the overlapping STAT site are required for Oas1a promoter induction by
IFN beta while Oas1b expression requires only the ISRE. Also, both STAT1 and STAT2 are
required for Oas1a upregulation by IFN beta, while only STAT2 is required for Oas1b
upregulation. A single nucleotide difference between the STAT sites of the Oas1b and Oas1a
promoters appeared to be responsible for the differential STAT1-dependence of Oas1a and
Oas1b expression.
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RESULTS
2.1

Mapping the Oas1a and Oas1b gene promoter regions required for basal promoter
expression and induction by IFN beta.

The Oas1a and Oas1b genes are ISGs and after treatment of C3H/He MEFs with 1000 U/ml of
murine IFN beta for 3 h, Oas1a mRNA was upregulated by about 9 fold while the Oas1b mRNA
was upregulated by about 7 fold (Fig. 2.1A). The time and the dose of IFN treatment was
selected based on a previous study showing that the highest level of ISG induction was at 3h
after IFN treatment of MEFs and that the levels of ISG mRNA upregulation were similar with
10, 100 and 1000 U/ml of IFN beta (Scherbik et al., 2007). The regions of the Oas1a and Oas1b
proximal promoters required for basal gene expression and activation by IFN beta were then
mapped using luciferase reporter assays. Two firefly luciferase reporter gene constructs, one
containing a C3H/RV Oas1a gene promoter fragment [Oas1a (-1768, +28)] and the other
containing a C3H/RV Oas1b gene promoter fragment [Oas1b (-1398, +51)], were first generated
and then a set of 5' sequentially deleted constructs was made for each promoter. C3H/RV MEFs
were transfected with construct DNA, and 24 h later cell lysates were harvested and used to
analyze basal promoter activity. To analyze the effect of IFN on Oas1 promoter activity, cells
transfected with a luciferase reporter for 24 h were incubated with murine IFN beta. Initial pilot
experiments showed that although luciferase activity was the highest at both 3 and 6 h after
treatment, the 3h peak level was the most reproducible. At 24 and 48 h, luciferase activity was
significantly decreased. Based on these preliminary results and the maximum half-life of the
firefly luciferase protein of 4 h (Thompson et al., 1991; Brandes et al., 1996), assays were done
in all subsequent luciferase reporter experiments after 3 h of IFN beta treatment. Low basal
luciferase activities were detected for both the longest Oas1a (-1768, +28) construct (Fig. 2.1B)
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Table 2.1. Primers used to generate the Oas1a and Oas1b promoter deletion reporter
constructs.
Construct
Oas1a (-854 to +28)
Oas1a (-722 to +28)
Oas1a (-641 to +28)
Oas1a (-468to +28)
Oas1a (-396 to +28)
Oas1a (-289 to +28)
Oas1a (-176 to +28)
Oas1a (-87 to +28)
Oas1b (-1398 to +51)
Oas1b (-991 to +51)
Oas1b (-814 to +51)
Oas1b (-742 to +51)
Oas1b (-507 to +51)
Oas1b (-394 to +51)
Oas1b (-181 to +51)
Oas1b (-116 to +51)
1

Forward primer
AGCTAGCTAGGCTCGGGGACCAGTAGTAG1
AGCTAGCGCCCATGAGTGATCCTCCA
AGCTAGCTCAACCTTGGGAATGTCCTGG
AGCTAGCGATGTGAGTAAGAGAGGGGGC
AGCTAGCAAAGAAAGAAAGAAAGGAAGAAAG
AGCTAGCTGGAAGCCACAGCCACCTTCTGCAG
AGCTAGCAGAAGAAACCCCAAGAAAGCCAG
AGCTAGCTGGTCAGAAGCTCTGAAGCC
AGCTAGCTTTTTCCCCCTCACACTCTG
AGCTAGCCCAATCCTGCTCTTGCAGAAGGC
AGCTAGCGTGTGTGTGTGTGTGTGTTTGGGAC
AGCTAGCACAGCCCGAGCTCTTAAACTCTGAG
AGCTAGCAGACCCCACCCTCACCCAGAC
AGCTAGCACCTGCAAGTCCAGAGGTAAAGG
AGCTAGCCAGAAGAAATCCCGAGAAAG
AGCTAGCGTACCTGTTCAGAAGCCCTAACGCC

Reverse primer
AAGATCTGCTAAGTCTGGAGCTTCCTGG1
AAGATCTGCTAAGTCTGGAGCTTCCTGG
AAGATCTGCTAAGTCTGGAGCTTCCTGG
AAGATCTGCTAAGTCTGGAGCTTCCTGG
AAGATCTGCTAAGTCTGGAGCTTCCTGG
AAGATCTGCTAAGTCTGGAGCTTCCTGG
AAGATCTGCTAAGTCTGGAGCTTCCTGG
AAGATCTGCTAAGTCTGGAGCTTCCTGG
AAGATCTCCTCTGCAGCCAGCAGGTCCT
AAGATCTCCTCTGCAGCCAGCAGGTCCT
AAGATCTCCTCTGCAGCCAGCAGGTCCT
AAGATCTCCTCTGCAGCCAGCAGGTCCT
AAGATCTCCTCTGCAGCCAGCAGGTCCT
AAGATCTCCTCTGCAGCCAGCAGGTCCT
AAGATCTCCTCTGCAGCCAGCAGGTCCT
AAGATCTCCTCTGCAGCCAGCAGGTCCT

Underlined sequences indicate an NheI restriction site included in all forward primers and a BglII restriction site included in the reverse primers.
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Figure 2.1. IFN beta-induced upregulation f Oas1a and Oas1b in vivo and of promoter
reporter constructs in vitro. (A) C3H/He MEFs were treated with 1000 U/ml of murine IFN
beta for 3h or left untreated (control). Total RNA was extracted and Oas1a and Oas1b mRNA
levels were measured by real time qRT-PCR. The mRNA level for each gene was normalized to
the level of GAPDH mRNA in the same sample and is shown as the fold change over the amount
of mRNA in mock samples expressed in relative quantification units (RQU). Each experiment
was performed in triplicate. Luciferase reporter assays were done with (B) Oas1a and (C) Oas1b
promoter fragments of different lengths. C3H/RV MEFs were co-transfected with either a
luciferase reporter construct DNA or a control empty vector DNA and Renilla luciferase reporter
vector DNA (transfection efficiency control). At 24 h after transfection, MEFs were either
treated with 1000 U/ml of murine IFN beta for 3 h or left untreated (control). Cell lysates were
prepared and firefly luciferase activity was measured in triplicate. Firefly luciferase activity was
normalized to Renilla luciferase activity for each sample. Error bars represent standard error of
the mean (SEM) (n=3). Significant differences were determined with a Student’s t test (, P <
0.05).
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and the longest Oas1b (-1398, +51) construct (Fig. 2.1C). These constructs showed a modest but
significant increase in promoter activity after IFN treatment. The observation that the longest
Oas1a and Oas1b promoter fragments tested produced the lowest reporter activities suggested the
presence of upstream transcriptional repressor elements that negatively affected the basal and
IFN-induced expression levels of both promoters.

Promoter constructs with sequential 5' deletions were used to determine the shortest Oas1a and
Oas1b promoter fragments able to produce increased luciferase activity upon stimulation with
IFN beta. Each of the 5' deleted Oas1a promoter constructs tested produced similar significantly
increased basal luciferase activities compared to the Oas1a (1768, +28) construct and the
activities for each of these constructs increased upon stimulation with IFN beta (Fig. 2.1B). For
instance, the Oas1a (-87, +28) and Oas1a (-854, +28) constructs had basal activities that were 7.1
and 8.6 fold higher, respectively, than that of the Oas1a (-1768, +28) construct and both showed
a 1.75 fold increase in luciferase activity after stimulation with IFN beta. These results indicated
that the TFBSs required for IFN induction of the Oas1a are located between -87 and +28.

In contrast to what was observed with the truncated Oas1a constructs, the activities of each of the
5' deleted Oas1b constructs varied. The Oas1b (-576, +51) construct showed a 21 fold increase
over the activity produced by the Oas1b (-1398, +51) construct (Fig. 2.1C). Constructs that were
either shorter or longer than Oas1b (-576, +51) produced lower basal activities. The observation
that the basal activity of the Oas1b (-116 to +51) construct was 2.5 fold lower than that of Oas1b
(-576, +51) suggested that the region between -576 and -116 contains elements that enhance
basal Oas1b expression. As the length of the Oas1b constructs increased beyond -576 bp, the
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basal activity decreased suggesting the presence of repressor elements in this region. The activity
of each of the truncated Oas1b promoter constructs was induced to a similar extent above its
basal level by IFN beta treatment (Fig. 2.1C) indicating that the elements required for the
induction of the Oas1b promoter by IFN beta are located between -116 and +51 bp.

Although the results obtained were reproducible and statistically significant, basal levels were
high and the maximal induction observed with IFN beta was about 2 fold. The low levels of
induction by IFN are likely to be due to the use of promoter fragments with only a single ISRE in
the context of a natural promoter sequence which also contains multiple additional TF binding
sites that modulate both basal and IFN-induced luciferase activity. Previous studies using natural
TLR9 (Guo et al., 2005) and RIG-I (Su et al., 2007) promoter sequences with single copies of an
ISRE also reported a 2 fold or lower activation of the reporter gene after stimulation with IFN
beta.
2.2

Analysis of the core promoter elements in the Oas1a and Oas1b promoters.

Elements in the -87 to +28 C3H/RV Oas1a promoter fragment and in the -116 to +51 C3H/RV
Oas1b promoter fragment were predicted with GENOMATIX and TFSEARCH programs.
Neither promoter contained a TATA box but each contained an INR (Fig. 2.2), an element
commonly found in TATA-less promoters and known to be able to direct transcriptional
initiation (Smale and Baltimore, 1989; Smale, 1997). Within the INR consensus
C

/TC/TA+1NA/TC/TC/T, the adenine is the transcription start site (TSS) and this nucleotide was used

to predict the location of the Oas1a and Oas1b TSSs. The GENOMATIX program also predicted
an inverted CCAAT element (ICE) at -63 to -68 in the Oas1a promoter and at -62 to -67 in the
Oas1b promoter. CCAAT boxes in either the forward (CCAAT) or reverse (ICE; ATTGG)
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Figure 2.2. Predicted TFBSs in the Oas1a and Oas1b promoters. TFBSs predicted by the
GENOMATIX search program. The locations of the DNA fragments with respect to the
predicted TSS in an INR are indicated with an arrow. Substituted nucleotides in both promoters
are underlined and substitutions made in promoter fragments are shown above arrows indicating
the boundaries of individual TFBSs.
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orientation are typically located about 60 to 100 nucleotides upstream of the TSS (Mantovani,
1999; Dolfini et al., 2009). To determine whether the predicted ICE plays a functional role in the
Oas1a and Oas1b promoters, two nucleotides (ATTGG → ATCCG) were substituted in this
element in the Oas1a (-854, +28) and Oas1b (-576, +51) constructs. A GENOMATIX search
confirmed that the introduced mutations eliminated the targeted binding site and did not create a
new TFBS. Mutation of ICE reduced the basal luciferase activity of the Oas1a and Oas1b
promoters by 43% and 40%, respectively, but did not negatively affect induction of either
promoter by IFN beta (Fig.2.3A). IFN beta induced the wild type and ICE-mutated Oas1a
promoters by 1.7- and 1.9 fold, respectively, and the wild type and ICE-mutated Oas1b promoter
by 1.4 and 1.5 fold, respectively.

DNA probes consisting of the -88 to -49 bp for Oas1a or -82 to -48 bp for Oas1b (Table 2.3)
were next used in an electrophoretic mobility shift assay (EMSA) to determine whether TFs bind
to the ICE sequence. Oas1a and Oas1b probes with a wild type ICE bound to two complexes in
nuclear extracts from untreated C3H/RV MEFs (Fig. 2.3B). With both probes, the upper band
was much darker than the lower band. These bands were either not detected or were much fainter
when a specific unlabeled competitor DNA was included in the reaction suggesting that the
binding detected was specific. Neither of the shift bands was observed when an Oas1a probe
containing a mutated ICE was tested. An Oas1b probe with a mutated ICE detected a faint lower
complex band but did not detect an upper complex band. The results suggest that nuclear extracts
from untreated control cells contain TFs that bind to the ICE. Although the TFs binding to the
ICE in the Oas1a and Oas1b promoters were not identified, both the reporter assay (Fig. 2.3A)
and the EMSA (Fig. 3B) results suggest that the ICE element plays a role in the regulation of
basal transcription from both genes.
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Table 2.2. Primers used for site directed mutagenesis.
Construct
Oas1a (-854, +28) mIRF
Oas1a (-854, +28) mISRE
Oas1a (-854, +28) mSTAT
Oas1a (-854, +28) mICE
Oas1b (-576, +51) mNF-kappa B
Oas1b (-576, +51) mIRF
Oas1b (-576, +51) mISRE
Oas1b (-576, +51) mSTAT
Oas1b (-576, +51) mICE

1
2

Primer
F1
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

Primer sequence
GCCCTTCTCGGGAAATGGAAACTGTACATCTACTTCCC2
GGGAAGTAGATGTACAGTTTCCATTTCCCGAGAAGGGC
GCCCTTCTCGGGAAATGGTACCTGAAAATCTACTTCCC
GGGAAGTAGATTTTCAGGTACCATTTCCCGAGAAGGGC
CATAGCCCTGCCCGTGTCGGCAAATGGAAACTG
CAGTTTCCATTTGCCGACACGGGCAGGGCTATG
CAGAAGCTCTGAAGCCATCCGCTGCCGGGGCCTGG
CCAGGCCCCGGCAGCGGATGGCTTCAGAGCTTCTG
CCCGGGAAATGGAAACTGAAAGGACCATTTCTGCTTCAGCG
CGCTGAAGCAGAAATGGTCCTTTCAGTTTCCATTTCCCGGG
CCCGGGAAATGGAAACTGTACGTCCCATTTCTGCTTCAGCG
CGCTGAAGCAGAAATGGGACGTACAGTTTCCATTTCCCGGG
GCCCTTCCCGGGAAATGGTACCTGAAAGTCCC
GGGACTTTCAGGTACCATTTCCCGGGAAGGGC
GCATATCCGCGCCCGTGCCGGCAAATGGAAACTGAAAGTCCC
GGGACTTTCAGTTTCCATTTGCCGGCACGGGCGCGGATATGC
CAGAAGCCCTAACGCCATCCGCTGCTCGGGCCTGG
CCAGGCCCGAGCAGCGGATGGCGTTAGGGCTTCTG

F, forward primer; R, reverse primer
Underlined letters indicate mutated nts.

Table 2.3. Sequences of DNA probes used in EMSA.
Gene
Oas1a
Oas1a
Oas1a
Oas1b
Oas1b
Oas1b

TFBS
ISRE
ICE
mutICE
ISRE
ICE
mutICE

Location
-31 to +7
-83 to -49
-83 to -49
-33 to +8
-82 to -48
-82 to -48

Sequence
GCCCTTCTCGGGAAATGGAAACTGAAAATCTACTTCCC
CAGAAGCTCTGAAGCCATTGGCTGCCGGGGCCTGG
CAGAAGCTCTGAAGCCATCCGCTGCCGGGGCCTGG
CGCCCTTCCCGGGAAATGGAAACTGAAAGTCCCATTTCTGC
CAGAAGCCCTAACGCCATTGGCTGCTCGGGCCTGG
CAGAAGCCCTAACGCCATCCGCTGCTCGGGCCTGG
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Figure 2.3. Functional analysis of the predicted Oas1a and Oas1b ICEs. (A) Luciferase
reporter assays were done with control and mutated ICE constructs. Two nts in the ICE of the
Oas1a (-854, +28) and Oas1b (-576, +51) constructs were substituted as indicated in Fig. 2. At
24 h after transfection of a wild type or mutant construct, C3H/RV MEFs were either treated
with murine IFN beta (1000 U/ml) for 3 h or untreated and then luciferase activities were
analyzed. Firefly luciferase activity measured in triplicate was normalized to Renilla luciferase
activity. Error bars represent SEM (n=3). Statistical significance was determined with a Student
‘s t test (, P < 0.05; , P < 0.005). (B) EMSA. DIG-labeled Oas1b and Oas1a DNA probes
containing either a wild type or mutated ICE and nuclear extracts from C3H/RV MEFs were
used for the binding reactions. A 200 fold excess of unlabeled specific competitor DNA was
added prior to addition of the probe in the indicated reactions. DNA-protein complexes were
resolved on 6% native gels and the bound labeled probe was detected using anti-DIG antibody.
The results shown are representative of at least two independent experiments.
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2.3

Comparison of the sequences of the Oas1a and Oas1b promoters in resistant C3H/RV
and susceptible C3H/He MEFs.

To determine whether the sequences of the Oas1a or Oas1b promoters differ between congenic
flavivirus disease susceptible C3H/He and flavivirus disease resistant C3H/RV mice, Oas1a (1768, +28) and Oas1b (-1398, +51) DNA fragments were amplified by PCR from MEFs from
each mouse strain, cloned and sequenced. Although complete identity was observed between the
C3H/RV and C57BL/6J (NT_078458.6) Oas1a and Oas1b promoter sequences, the C3H/He
Oas1a promoter sequence differed by T to C substitutions at positions -66 and -298 and the
C3H/He Oas1b promoter sequence differed by a G to C substitution at position +15 and a 4 nt
deletion between -327 and -323. GENOMATIX and TFSEARCH TFBS searches of the C3H/He
promoter sequences predicted that only the T to C substitution at -66 in the Oas1a promoter was
located in a TFBS. This substitution changed the ICE from ATTGG to ATCGG. Based on the
observation that mutation of the ICE from ATTGG to ATCCG significantly decreased the basal
activities of both the C3H/RV Oas1a and Oas1b promoters, the single nucleotide substitution in
the C3H/He Oas1a promoter producing a ATCGG ICE sequence would be expected to reduce
the basal expression level of the Oas1a gene in C3H/He MEFs.

2.4

Analysis of transcription factors binding to the Oas1a and Oas1b promoters.

Both the previously published search (Mashimo et al., 2003) and the TFSEARCH and
GENOMATX TFBS searches done in this study predicted canonical ISREs with identical
sequences (5' GGGAAATGGAAACT 3') between -22 to -9 bp in the Oas1a promoter and
between -23 to -10 bp in the Oas1b promoter (Fig. 2B). To determine whether the components of
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Figure 2.4. Binding of STAT1 and STAT2 to the Oas1a and Oas1b promoters in in viro and
in vivo. DIG-labeled Oas1b and Oas1a DNA probes and nuclear extracts from untreated or
murine IFN beta (1000 U/ml) treated C3H/RV MEFs were used for EMSA. Anti-STAT1, antiSTAT2 or a nonspecific IgG antibody was added to the nuclear extract prior to addition of the
probe. DNA-protein complexes were resolved on 6% native gels and the labeled probe was
detected with anti-DIG antibody. The results shown are representative of at least two
independent experiments. ChIP analysis of the binding of STAT1 or STAT2 to the (B) Oas1a or
(C) Oas1b promoter in control or 30 min IFN beta-treated C3H/He cells. The amounts of
precipitated Oas1a and Oas1b promoter DNA were quantified by real-time qPCR using
promoter-specific primers and fluorogenic TaqMan FAM/MGB probes. Nonspecific IgG
antibody was used as a negative control and averaged values are shown. The error bars represent
standard deviation of the mean (SDM) (n=3).
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the ISGF3 complex bind to the predicted Oas1a and Oas1b ISREs, -31 to +6 bp Oas1a and -32 to
+5 bp Oas1b DNA fragments were used as probes in EMSAs with nuclear extracts from
untreated or murine IFN beta-treated MEFs. Two bands were detected with the Oas1a probe and
three with the Oas1b probe using nuclear extracts from IFN-treated cells (Fig. 4A). However, the
upper complex band was not observed with either probe when the reaction was done with
nuclear extracts from untreated cells. To determine whether the STAT1 and STAT2 transcription
factors were present in one or more of these bands, nuclear extracts were incubated with either
anti-STAT1 or anti-STAT2 antibody prior to addition of the probe. With the Oas1a probe, the
upper band was not detected when STAT1 antibody was present, and a supershift band
(indicated by an arrow) was observed when STAT2 antibody was present. With the Oas1b probe,
a decrease in the intensity of the upper band was observed when STAT1 antibody was added and
a supershift band was detected when the STAT2 antibody was added. The addition of a
nonspecific rabbit IgG did not alter the band patterns of either probe. The results suggested that
both STAT1 and STAT2 were present in the upper complex band detected by both probes. In
order to confirm the validity of the supershift data the binding of STAT1 and STAT2 to the
ISREs in the Oas1a and Oas1b promoters in cells stimulated with IFN beta was analyzed by
ChIP (Fig. 2.4B and C). Pilot ChIP experiments showed that the levels of STAT1 and STAT2
bound to these ISG promoters was higher at 30 m than at 3 h after treatment with IFN beta.
C3H/He cells were left untreated or treated with 1000 U/ml of IFN beta for 30 m and then treated
with formaldehyde. Crosslinked DNA- protein complexes were immunoprecipitated using antiSTAT1, anti-STAT2 or a nonspecific IgG antibody. The crosslinks were reversed and the
immunoprecipitated DNA was purified and quantified by real time qPCR. The results showed
that both STAT1 and STAT2 are present on the Oas1a and Oas1b promoters after stimulation of
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the C3H/He cells by IFN beta. Although one of the two anti-IRF-9 antibodies (Santa Cruz
Biotechnology) tested detected IRF-9 in Western blots, neither of these antibodies was found to
be suitable for EMSA nor ChIP, therefore the interaction of IRF-9 with the ISREs of these
promoters could not be directly tested.
2.5

Functional analysis of TFBSs predicted in the Oas1a and Oas1b promoters.

The GENOMATIX search done in the present study predicted a STAT site overlapping the 5'
end and an IRF site overlapping the 3' end of both the Oas1a and Oas1b ISREs (Fig. 2.2). These
predictions suggested that the sequences located immediately upstream and downstream of the
ISRE might be important for stabilizing the binding of STAT1 and IRF-9 to the core ISRE
and/or for facilitating the binding of additional STAT and IRF factors. To functionally test these
predictions, the ISRE and overlapping STAT and IRF TFBSs were individually mutated in the
Oas1a (-854, +28) and Oas1b (-576, +51) constructs as indicated in Fig. 2. The luciferase activity
of each mutated reporter construct after stimulation with murine IFN beta was compared to that
of the wild type construct. A GENOMATIX search confirmed that the introduced mutations
eliminated the targeted binding site but did not create a new TFBS. Mutation of the ISRE (3'
GAAA to 3' GTAC) in the Oas1a (Fig. 5A) and Oas1b (Fig. 2.5B) constructs reduced the basal
activities of both promoters by more than 80% suggesting that the ISRE plays a role in
modulating the basal expression of Oas1a and Oas1b. Low levels of IFN were previously
reported to be secreted by unstimulated, cultured MEFs (Takaoka and Yanai, 2006) and this
could explain the negative effect of the ISRE mutation on basal expression. No increase in
activity above basal levels was observed for either the Oas1a or Oas1b promoter with a mutated
ISRE after stimulation with IFN beta confirming that the ISRE is required for IFN beta-induction
of both genes.
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Figure 2.5. Effect of mutation of the ISRE or overlapping/adjacent TFBSs on Oas1a and
Oas1b promoter activity. Individual TFBSs were mutated in reporter constructs as indicated in
Fig. 2. The luciferase activities of control and mutated (A) Oas1a and (B) Oas1b reporter
constructs were assayed. Each construct was transfected into C3H/RV cells and 24 h after
transfection, cells were treated with 1000 U/ml of murine IFN beta for 3 h or left untreated.
Firefly luciferase activity was measured in triplicate and normalized to Renilla luciferase
activity. The values shown are the average of three independent experiments. Error bars
represent SEM (n=3). Statistical significance was determined with a Student’s t test (, P < 0.05;
, P < 0.005)
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The predicted IRF site overlapping the 3' end of the ISRE was mutated at the -5 and -7 positions
in the Oas1a promoter and at the -6 and -8 positions in the Oas1b promoter (Fig. 2.2). Although
mutation of the IRF site resulted in about a 50% reduction in basal Oas1a and Oas1b promoter
activity, both mutated promoters were efficiently upregulated by IFN (Fig. 2.5). IFN beta
induced the wild type Oas1a construct activity by 1.7 fold and that of the Oas1a IRF mutant
construct by 2.1 fold. Both the wild type and mutant IRF Oas1b constructs showed a 1.3 fold
induction after IFN treatment. These results indicate that the IRF binding site overlapping the
ISRE in both promoters positively regulates basal promoter activity, but does not contribute to
the induction of these promoters by IFN beta.

Mutations were next introduced into the STAT site overlapping the 5' end of the Oas1a and
Oas1b ISREs. Substitutions were introduced at positions -20, -25 and -27 in the Oas1a promoter
and at positions -21, -26 and -28 in the Oas1b promoter (Fig. 2.2). Similar to what was observed
for the Oas1a construct with a mutated ISRE, the Oas1a mutant STAT construct showed a more
than an 80% reduction in basal activity but was not upregulated by IFN beta. In contrast,
mutation of the STAT site in the Oas1b promoter only minimally affected basal or IFN betainduced activities. These results suggest that the STAT site overlapping the Oas1a ISRE is
required for the induction of this promoter by IFN beta, while the STAT site overlapping the
Oas1b ISRE is not.

The TFBS searches done by Mashimo et al. (2003) and those done in the present study predicted
an NF-kappa B site immediately downstream of the Oas1b ISRE but not of the Oas1a ISRE. The
sequence of this site differs from the NF-kappa B consensus GGGA/GNNC/TC/TCC (Grilli et al.,
1993) at the two underlined positions (Fig. 2). Type 1 IFN binding to the IFN alpha/beta receptor
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has been reported to also activate the phosphatidylinositol 3 kinase (PI3K) pathway (Kaur et al.,
2005) which was shown to play a role in activating NF-kappa B (Chang et al., 2006). The Oas1b
NF-kappa B site was mutated as indicated in Fig. 2. The luciferase activity observed for this
mutant construct was the same as that for the wild type construct with and without IFN treatment
(Fig. 2.5B). These results indicate that the NF-kappa B site does not modulate the induction of
the Oas1b promoter by IFN beta and does not affect basal activity.

2.6

IFN beta-induction of the Oas1a and Oas1b genes in the absence of STAT1 or
STAT2.

As one means of determining whether STAT1 is required for the activation of the Oas1a and
Oas1b genes by IFN beta, the expression of these genes was analyzed by real time qRT-PCR in
wild type, STAT1-/- and STAT2-/- MEFs. In wild type MEFs, Oas1a and Oas1b gene expression
was efficiently induced by IFN beta (Fig. 2.6A). Basal levels of Oas1a mRNA were not
detectable in either untreated STAT1-/- or STAT2-/- MEFs and minimal upregulation of Oas1a
expression was observed after incubation of these cells with IFN beta. Basal levels of Oas1b
were detected in both STAT1-/- and STAT2-/- MEFs. Although IFN beta did not upregulate
Oas1b expression in STAT2-/- MEFs, it efficiently upregulated Oas1b expression in STAT1-/MEFs. To confirm these observations, the binding of STAT1 and STAT2 to the Oas1a and
Oas1b promoters in control, STAT-/- and STAT2-/- MEFs was analyzed by ChIP. Both STAT1
and STAT2 bound the Oas1a and Oas1b promoters in IFN beta-treated control 129 MEFs but
neither bound to either promoter in the STAT2-/- MEFs (Fig.2.6B and C). In contrast, STAT2
bound to the Oas1b promoter but not to the Oas1a promoter in STAT1-/- MEFs confirming that
Oas1a promoter induction by IFN beta occurs in a STAT1- and STAT2-
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Figure 2.6. Analysis of the inductionof Oas1a and Oas1b by IFN beta in wild type, STAT1/- and STAT2-/- MEFs. MEFs were treated with 1000 U/ml of murine IFN beta for 3 h or left
untreated. Total RNA was collected and fold induction of Oas1a and Oas1b mRNA expression
levels was measured by real-time qRT-PCR. The mRNA level of each gene was normalized to
the level of GAPDH mRNA in the same sample. The fold change over the amount of mRNA in
mock samples is expressed in RQU. Each experiment was performed in triplicate. ND - not
detected. ChIP analysis of the binding of STAT1 or STAT2 to the (B) Oas1a or (C) Oas1b
promoter in control 129, STAT1-/- and STAT2-/- MEFs mock-treated or treated with 1000 U/ml
of IFN beta for 30 min. The amounts of precipitated Oas1a and Oas1b promoter DNA were
quantified by real-time qPCR using promoter specific primers and fluorogenic TaqMan
FAM/MGB probes. Nonspecific IgG antibody was used as a negative control and averaged
values are shown. The error bars represent SDM (n=3).
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dependent manner, while the induction of Oas1b by IFN beta is STAT2-dependent but can be
STAT1-independent.

DISCUSSION
The mouse genome contains 8 duplications of the Oas1 gene. As an active 2-5 A synthetase
murine Oas1a functions as a broad spectrum antiviral protein through its ability to activate
RNase L (Kakuta et al., 2002). Oas1b is an inactive synthetase that can function in a dominant
negative manner to suppress Oas1a synthetase activity (Elbahesh et al., 2011). Oas1b also
provides flavivirus-specific antiviral activity through an as yet uncharacterized mechanism that
does not involve the RNase L pathway (Scherbik et al., 2006). Based on TFBS differences
identified in the Oas1a and Oas1b promoters, a previous study predicted that these two genes
may be differentially activated by IFN and/or virus infection but this hypothesis was not
functionally tested (Mashimo et al., 2003). In the present study, a firefly luciferase reporter assay
and truncated and mutated promoter constructs were used to map the Oas1a and Oas1b promoter
regions required for basal activity and IFN beta induction. For both genes, the lowest basal
promoter activity was observed with the longest promoter fragment tested but activity increased
significantly with 5' truncation suggesting the presence of binding sites for transcriptional
repressors in the upstream region. Deletion of the 5' upstream region was previously reported a
prerequisite for mapping the activation sites in the proximal promoters of the interleukin 19 and
fucosyltransferase VI genes (Chen et al., 2006; Higai et al., 2008). Upstream sites that repress the
transcriptional activation by TFs binding to TFBSs in the proximal promoter region were also
previously identified in the promoters of genes for which transcription is known to be tightly
regulated (Garban and Bonavida, 2001; Lindas and Tomkinson, 2007). Since activation of the
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RNase L pathway by 2-5A leads to degradation of not only viral but also cellular ssRNAs, it
would be expected that the expression of the Oas1 genes would be tightly regulated.

The core promoters of the Oas1a and Oas1b genes contain an INR element and an inverted ICE.
Mutation of the ICE element reduced the basal activities of the Oas1a and Oas1b promoters by
about 40% but did not affect the induction of either promoter by IFN beta suggesting that ICE
plays a role in basal promoter activity but not in IFN-mediated induction. The EMSA results
showed that TFs in control cell nuclear extracts bound to a probe with a wild type but not a
mutated ICE sequence. Although the identities of the TFs were not determined, NF-Y, also
termed CBF (CCAAT binding factor), was previously shown to be the primary TF binding to the
CCAAT element in either orientation (Mantovani, 1999). NF-Y is a ubiquitous transcription
factor composed of three subunits that can increase the DNA binding affinity of factors bound to
neighboring TFBSs (Reith et al., 1994; Wright et al., 1995; Jackson et al., 1998) and interact
with p300/CBP, GCN5 and PCAF complexes that mediate promoter acetylation (Currie, 1998;
Jin and Scotto, 1998; Li et al., 1998; Salsi et al., 2003). NF-Y has also been reported to recruit
RNA polymerase II to a promoter (Kabe et al., 2005). The mutation identified in the ICE of the
C3H/He Oas1a promoter suggests that the basal levels of Oas1a expression would be reduced in
the cells of these mice.

Deletion analysis of the Oas1b promoter showed that the regulation of this gene is more complex
than that of the Oas1a gene. The mapping data indicated that the region of the Oas1b promoter
between -576 and -116 contains elements that enhance basal Oas1b expression. TFBSs predicted
by TFSEARCH and GENOMATIX in this region of the Oas1b promoter that were not found in
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the Oas1a promoter include C/EBPb, GATA-1, AML-1, CdxA, HSF2, IK-2, Lyf-1, and MZF-1.
C/EBPb (also known as CCAAT/enhancer-binding protein beta) was previously shown to
positively regulate gene induction by recruiting transcriptional coactivators as well as basal
transcription factors (Kowenz-Leutz and Leutz, 1999).

Upon type I IFN stimulation, the transcription factor complex ISGF3, composed of STAT1,
STAT2 and IRF-9, binds to ISREs in ISG promoters with the consensus sequence 5'
A

/GNGAAANNGAAACT 3' (Darnell et al., 1994). The Oas1a and Oas1b promoters were each

predicted to have a single canonical ISRE by a previous TFSEARCH (Mashimo et al., 2003) and
also by both the GENOMATIX and TFSEARCH database searches done in the present study.
Since the structure of ISGF3/DNA complex has not yet been solved is not clear exactly how the
ISGF3 complex components bind to the ISRE. It was previously reported that STAT1 recognizes
the 5' GAAA sequence and IRF-9 recognizes the 3' GAAA sequence in the ISRE. STAT2 does
not stably bind to DNA but interacts with both STAT1 and IRF-9 and is essential for the
transcriptional activity of the ISGF3 complex (Bluyssen et al., 1995; Qureshi et al., 1995). The
substitutions introduced into the ISRE 3' GAAA in both the Oas1a and Oas1b promoters
abolished IFN beta induction indicating that this region is required for IFN beta induction of
these ISGs. A GAS site was previously predicted to overlap the 5' end of the Oas1b ISRE but not
that of the Oas1a (Mashimo et al., 2003). GAS elements were originally identified in the
promoters of IFN-gamma responsive genes. Upon IFN-gamma stimulation, a STAT1
homodimer, also referred to as the gamma interferon activation factor (GAF), was shown to bind
to GAS elements with the consensus sequence TTCN2-4GAA (Decker et al., 1997). Although
other STATs can bind to this consensus sequence, the DNA binding specificities of different
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STAT proteins depends on the length of the spacer sequence and specific nucleotides in both the
binding site and immediately adjacent to it (Darnell, 1997; Decker et al., 1997; Ehret et al.,
2001). The GENOMATIX search done in this study predicted a STAT binding site overlapping
the 5'GAAA motif of the ISRE in both the Oas1a and Oas1b promoters. Substitution of the G in
this ISRE motif was reported to prevent the binding of STAT1 but not of the IRF-9/STAT2
complex (Bluyssen and Levy, 1997). Mutation of the Oas1a STAT site including the G
mentioned above abolished IFN beta-induced promoter activity suggesting that the binding of
STAT1 is crucial for the induction of this promoter by IFN beta. In contrast, mutation of the
same nucleotides in the Oas1b STAT site did not significantly reduce upregulation by IFN beta.
Consistent with these observations, the Oas1b gene but not the Oas1a gene was efficiently
upregulated in IFN-treated STAT1-/- MEFs confirming that the induction of Oas1b by IFN beta
does not require STAT1.

Although the sequences of the Oas1a and Oas1b ISREs are identical, the STAT sites overlapping
the 5' ISRE GAAA motif differ by one nt, Oas1a (TTCTCGGGAA) and Oas1b
(TTCCCGGGAA). A previous report proposed that the presence of an A, G or T at this position
promotes STAT2 binding (Tenoever et al., 2007). However, the finding in the present study that
IFN beta activation of the Oas1a promoter with a T in this position is STAT1-dependent while
activation of the Oas1b promoter with a C in this position is STAT1-independent suggests that
this site is important for stabilizing STAT1 binding and that the substitution at this site is
responsible for the differential STAT1 dependence between these two promoters. Although other
ISGs, such as Adar1, APOBEC3G and Irf7, were previously reported to be upregulated by type I
IFN in a STAT1-independent manner, the TF complexes involved in the STAT1-independent
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activation of ISGs by type I IFN have not yet been well characterized (Ousman et al., 2005;
Sarkis et al., 2006; George et al., 2008). Expression of a IRF-9/STAT2 fusion protein efficiently
activated the transcription of an ISRE-dependent luciferase reporter in the absence of type I IFN
stimulation (Kraus et al., 2003). Also, an IRF-9/STAT2 complex was sufficient to induce the
expression of a reporter construct containing the RIG-G gene promoter upon stimulation with
IFN alpha (Lou et al., 2009). However, it is currently not known whether additional factors are
also involved in STAT1-independent upregulation of ISGs by type I IFN.

The GENOMATIX search predicted an IRF binding site overlapping the 3'GAAA motif of the
ISRE in both the Oas1a and Oas1b promoters and an NF-kappa B binding site immediately
downstream of the Oas1b ISRE. Although these sites were not found to be involved in gene
activation by IFN, they may be involved in the upregulation of these genes in virus-infected
cells. It was previously reported that IRF-3, IRF-7 and NF-kappa B transcription factors are
activated during viral infections and mediate induction of type I IFN as well as upregulate a
subset of ISGs independently of IFN (Nakaya et al., 2001; Grandvaux et al., 2002; Peters et al.,
2002; Barnes et al., 2004; Elco et al., 2005; Andersen et al., 2008; Basagoudanavar et al., 2011).

Low levels of IFN produced by uninfected cells are required for maintaining basal levels of ISGs
(Taniguchi and Takaoka, 2001). Low level constitutive expression of ISGs in uninfected cells is
thought to be crucial for mounting an effective antiviral response in the initial stages of a virus
infection (Basagoudanavar et al., 2011). However, the data obtained in this study indicated that
basal expression of neither Oas1a nor Oas1b is solely dependent on type I IFN. Many viruses
antagonize type I IFN signaling and the induction of antiviral ISGs by blocking the activation of
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the Jak-STAT signaling pathway (Randall and Goodbourn, 2008; Diamond, 2009). The
observation made in this study that Oas1b and in previous studies, showing some other ISGs can
be induced by type I IFN in a STAT1-independent manner indicates that an effective antiviral
response can still be mounted in infected cells when STAT1 activation/translocation is blocked.
The importance of an alternative STAT1-independent response in providing host protection was
reported for dengue virus (another flavivirus) in a mouse model (Perry et al., 2011). However,
other types of viruses, such as measles virus and lymphocytic choriomeningitis virus, have been
reported to enhance their survival by suppressing dendritic cell development and expansion
through a STAT2-dependent but STAT-1-independent pathway (Hahm et al., 2005).
MATERIALS AND METHODS
2.7

Cells.

SV40-T antigen transformed C3H/He and C3H/RV MEFs were grown in minimal essential
medium (MEM) supplemented with 5% fetal bovine serum (FBS) and 10 µg/ml gentamicin.
Transformed 129/SvEv, STAT1-/- and STAT2-/- MEF lines (provided by Christian Schindler,
Columbia University, New York, NY) were grown in MEM supplemented with 10% FBS and
1% PenStrep (Gibco).
2.8

Quantification of mRNA levels.

Real time quantitative reverse transcription-PCR (qRT-PCR) analyses of mouse Oas1a and
Oas1b gene expression were performed using 50 µl reaction mixture containing 500 ng of total
cellular RNA, the primer pair (1 µM), and the probe (0.2 µM) in an Applied Biosystems 7500
Sequence Detection System. Applied Biosystems Assays-on-Demand 20x primer and fluorogenic
TaqMan FAM/MGB probe mixes (Mn00836412_m1 for Oas1a and Mn00449297_m1 for
Oas1b) were used. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as
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an endogenous control for each sample and was detected using TaqMan mouse GAPDH primers
and probe (Applied Biosystems). One-step RT-PCR was performed for each target gene and for
the endogenous control in a singleplex format using 200 ng of RNA and the TaqMan One-Step
RT-PCR Master Mix Reagent Kit (Applied Biosystems). The cycling parameters were as
follows: reverse transcription at 48°C for 30 m, AmpliTaq activation at 95°C for 10 m,
denaturation at 95°C for 15 s, and annealing/extension at 60°C for 1 m (cycle repeated 40 times).
The values were normalized to those for GAPDH and presented as the relative fold change
compared to the uninfected calibrator sample in relative quantification (RQ) units.
2.9

Cloning the Oas1a and Oas1b gene promoter regions.

A DNA fragment consisting of 1768 bp upstream and 28 bp downstream of the Oas1a gene TSS
and a fragment consisting of 1398 bp upstream and 51 bp downstream of the Oas1b TSS were
amplified from C3H/He and C3H/RV genomic DNA using primers designed from the GenBank
C57BL/6J mouse genomic sequence [(NCBI) Genbank ID: NT_078458.6]. The amplified PCR
products were cloned into a TopoXL vector (Invitrogen) and sequenced. The C3H/RV DNA
fragments were then subcloned into the pGL4.17 firefly luciferase reporter vector (Promega)
using NheI and BgLII cloning sites to generate the Oas1a (-1768, +28) and Oas1b (-1398, +51)
reporter constructs. These two constructs were subsequently used as templates in additional PCR
reactions to amplify DNA fragments containing sequential 5' deletions. Each of the deleted PCR
products was then cloned into the pGL4.17 firefly luciferase reporter vector to generate eight
additional Oas1a reporter constructs [Oas1a (-854, +28), Oas1a (-722, +28), Oas1a (-641, +28),
Oas1a (-468, +28), Oas1a (-396, +28), Oas1a (-289, +28), Oas1a (-176, +28) and Oas1a (-87,
+28)] and eight additional Oas1b reporter constructs [Oas1b (-991, +51), Oas1b (-814, +51),
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Oas1b (-742, +51), Oas1b (-576, +51) Oas1b (-507, +51), Oas1b (-394, +51), Oas1b (-181, +51),
and Oas1b (-116, +51)]. The primers used for these PCR reactions are listed in Table 2.1.
2.10 Prediction and mutation of TFBSs.
The TFSEARCH (version 1.3) and GENONATIX programs were used to predict TFBSs in the
Oas1a and Oas1b promoter fragment sequences. Specific mutations in predicted IRF, ISRE,
STAT and ICE binding sites (Fig. 2.2) were introduced into the promoter sequence in the Oas1a
(-854, +28) construct to generate the Oas1a (-854, +28) mIRF, Oas1a (-854, +28) mISRE, Oas1a
(-854, +28) mSTAT and Oas1a (-854, +28) mICE reporter constructs, respectively. Specific
mutations in the predicted NF-kappa B, IRF, ISRE, STAT and ICE binding sites (Fig 2.2) were
introduced into the Oas1b (-576, +51) construct to generate the Oas1b (-576, +51) mNF-kappa
B, Oas1b (-576, +51) mIRF, Oas1b (-576, +51) mISRE, Oas1b (-576, +51) mSTAT Oas1b (-576,
+51) mICE constructs, respectively. The mutations were introduced using the primers shown in
Table 2.2 and a QuikChange II Site-Directed Mutagenesis Kit (Stratagene) according to the
manufacturer's protocol. The mutant promoter sequences were analyzed using GENOMATIX
software to ensure that the substitutions introduced eliminated the targeted binding site but did
not create a new TFBS. The sequences of all the constructs generated were verified by DNA
sequencing.
2.11 Luciferase reporter assay.
The pGL4.17 firefly luciferase reporter plasmid DNA (1 g) containing either an Oas1a or
Oas1b promoter fragment and 20 ng of a pGL4.74 Renilla luciferase reporter construct DNA
(Promega) in a solution consisting of 3 l of FuGENE 6 (Roche Applied Science) and 97 l of
serum free media were added to C3H/RV MEF cultures (50-70% confluency) and the cells were
incubated at 37C for 24 h. Murine recombinant IFN beta (1000 U/ml) (PBL Interferon Source)
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was added to the cell cultures 21 h after transfection. After a 3 h incubation, cells were harvested
using the lysis buffer supplied with the Dual Luciferase Reporter Assay System (Promega).
Firefly and Renilla luciferase activities were separately measured according to the manufacturer's
protocol using a luminometer (LMax II384, Molecular Devices). The firefly luciferase activity
was normalized to the Renilla luciferase activity in each sample.
2.12 EMSA
The Oas1a and Oas1b DNA probes (Table 2.3) were labeled using a DIG gel shift 2nd generation
kit (Roche Applied Science) according to the manufacturer’s instructions. Nuclear extracts (2
g) prepared from C3H/RV MEFs that were either untreated or treated with 1000 U/ml of
murine IFN beta for 1 h were used for EMSA. The specificity of the binding detected was
analyzed by addition of a 200 fold excess of unlabeled probe to one of the reactions. For
supershift assays, nuclear extracts were incubated with anti-STAT1 (Santa Cruz Biotechnology
Inc.), anti-STAT2 (provided by Christian Schindler, Colombia University, New York, NY) or a
nonspecific IgG antibody (Zymed) for 30 m at room temperature. Binding reactions were
prepared according to the DIG gel shift 2nd generation kit protocol. DNA-protein complexes
were resolved on a 6% native polyacrylamide gel and labeled probe was detected using the antiDIG antibody supplied with the kit.
2.13 ChIP.
Confluent C3H/He monolayers were incubated with 1000 U/ml of murine IFN beta for 30 min or
left untreated. Chromatin was crosslinked in situ with 1% formaldehyde for 10 min at ~25°C.
After washing with ice cold phosphate-buffered saline (PBS), cells were incubated with 1 ml of
cell lysis buffer [5 mM PIPES pH 8.0, 85 mM KCl, 0.5% NP40 and Complete EDTA-free
Protease Inhibitors (Roche Applied Sciences)] for 10 m and the nuclei were pelleted at 2000 rpm

51

at 4°C. Nuclei were then incubated with SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris
pH 8.0, and Complete EDTA-free Protease Inhibitors) for 20 m on ice. The crosslinked
chromatin was sonicated to an average size of 500−1,000 base pairs. Sonicated chromatin
obtained from 1 x 106 cells was used for each immunoprecipitation reaction. Samples were first
precleared with 60 μl of salmon sperm DNA-coated agarose beads (Millipore) and then
incubated with 5 μg of anti-STAT1 (Santa Cruz Biotechnology), anti-STAT2 (provided by
Christian Schindler, Columbia University, New York, NY) or rabbit nonspecific IgG antibody
overnight at 4°C. After incubation with 60 μl salmon sperm-coated agarose beads, the samples
were washed sequentially for 5 m at 4°C with each of the following buffers: low salt buffer
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8.0 and 150 mM NaCl), high salt
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris, pH 8.0 and 500 mM NaCl) and
LiCl buffer (0.25 M LiCl, 1% NP40, 1% DOC, 1 mM EDTA and 10 mM Tris, pH 8.0). Finally,
the samples were washed twice with TE buffer (1 mM EDTA and 10 mM Tris, pH 8.0), and then
eluted with 500 μl of SDS elution buffer (1% SDS, 0.1 M NaHCO3). Samples were incubated
with 20 l of 5 M NaCl at 65°C overnight to reverse the crosslinks, then 10 l of 500 mM
EDTA, 20 l of Tris pH 6.5, and 2 l of Proteinase K (10 mg/mL) were added and the samples
were incubated for 1 h at 45°C. Input and immunoprecipitated DNA were isolated using a
phenol:chloroform:isoamyl alcohol mixture (USB Biochemicals) according to the manufacturer's
protocol and analyzed by real time quantitative PCR (qPCR) using probes and primers designed
to span the proximal Oas1a and Oas1b promoters. The sequences of the primers were: Oas1a
forward primer 5'-GGATCCTAAGAAAGCTCAGACTTCA-3', Oas1a reverse primer 5'CCCGGCAGCCAATGG-3', Oas1b forward primer 5'- GAAGCCCTAACGCCATTGG-3',
Oas1b reverse primer 5'-AGGGCGCGGATATGCA-3'. The sequence of the FAM-MGB Oas1a
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probe was 5'-TGGAAGTGTGGGAAAGGTCTTT-3' and that of the Oas1b probe was 5'CGGGCCTGGATGAT-3'. To generate standard curves, known amounts of Oas1a, Oas1b and
Irf7 promoter DNA in a TOPO-XL vector (Invitrogen) were titrated and assayed by real time
qPCR using a FastStart Universal Probe Master (ROX) kit (Roche Applied Science) according to
the manufacturer's protocol. The standard curves were independently generated at the same time
as the immunoprecipitated DNA samples were assayed by qPCR and used to quantify the
immunoprecipitated DNA.
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CHAPTER 3
3

AIM 2: Investigation of the activation of ISGs in MEFs infected with WNV Eg101.

INTRODUCTION
The family Flaviviridae, genus Flavivirus, contains several human pathogens including West
Nile virus (WNV), dengue virus, yellow fever virus (YFV), Japanese encephalitis virus (JEV)
and tick borne encephalitis virus (TBEV). WNV is a mosquito-borne virus that is transmitted in a
bird-mosquito cycle but occasionally mammals including humans and horses are infected. WNV
infections in humans are usually asymptomatic but can induce a mild febrile illness; however,
some patients develop encephalitis or a poliomyelitis-like disease. WNV particles contain a
single-stranded, positive-sense RNA genome encoding a single polyprotein that is cleaved by
viral and cellular proteases into three structural and seven nonstructural proteins (Brinton, 2002).
WNV isolates have been divided into two main lineages. Lineage I strains are often associated
with outbreaks of human disease, while the majority of lineage II strains are non-emerging and
cause zoonotic infections in Africa (Brinton, 2002).
IFNs were first discovered as cytokines that inhibit viral replication (Isaacs and Lindenmann,
1957). Induction of type I IFNs is primarily triggered by pattern recognition receptors (PRRs)
that recognize viral nucleic acids. Viral double stranded RNA (dsRNAs) or single stranded
RNAs (ssRNAs) are recognized by cytoplasmic PRRs, such as retinoic acid inducible gene-I
(RIG-I) and melanoma differentiation antigen 5 (MDA5), or by cell surface and endosomal
PRRs, such as Toll-like receptor 3 (TLR-3), TLR7 and TLR-8 (Saito and Gale, 2007).
Recognition of viral nucleic acids by these PRRs leads to activation of the TFs, IRF-3, NF-kappa
B and ATF2/c-Jun (AP1), that assemble on the IFN-beta promoter and activate IFN-beta gene
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expression (Merika and Thanos, 2001). Secreted IFN beta binds to cell surface IFN alpha/beta
receptor (IFN alpha/beta R) complexes inducing activation of receptor-associated Jak kinases
followed by recruitment and phosphorylation of the TFs, STAT1 and STAT2. STAT1, STAT2
and IFN regulatory factor-9 (IRF-9) form a trimeric transcription factor complex referred to as
IFN stimulated gene factor 3 (ISGF3) that translocates to the nucleus and binds to IFNstimulated response elements (ISREs) in the promoters of IFN-stimulated genes (ISGs) (Stark et
al., 1998). The induction of IFN-beta is biphasic due to the induction of ISGs, such as IRF-7,
which enhance IFN beta gene expression and sustain ISG production. IRF-7 also induces the
expression of IFN-alpha which amplifies the type I IFN response via a positive feedback loop
(Marie et al., 1998; Sato et al., 2000).
The expression of IFN-beta and multiple interferon stimulated genes (ISGs), many of which have
antiviral functions, represents the first line of defense against a viral infection. Many viruses
suppress this innate immune response by blocking the Jak-STAT signaling pathway. Different
flaviviruses were reported to block this pathway by either inhibiting Jak phosphorylation (Lin et
al., 2004; Best et al., 2005; Guo et al., 2005; Ho et al., 2005), reducing the expression of STAT2
(Jones et al., 2005; Mazzon et al., 2009) or blocking STAT1 and STAT2 phosphorylation
(Munoz-Jordan et al., 2003; Best et al., 2005; Liu et al., 2005; Munoz-Jordan et al., 2005). The
lineage I WNV strains TX02 and NY99 were previously shown to effectively block STAT1
phosphorylation in primate cells (Laurent-Rolle et al.; Liu et al., 2005; Keller et al., 2006). In
contrast, WNV Eg101, a lineage I stain closely related to NY99 but less neurounvasive (Beasley
et al., 2002) was previously reported not to inhibit STAT1 phosphorylation in mouse cells .
(Scherbik et al., 2006; Scherbik et al., 2007). However, the effects of WNV Eg101 infection on
STAT2 phosphorylation and ISGF3 nuclear translocation in these cells were not investigated.
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Inhibition of the Jak-STAT signaling pathway by a viral infection would be expected to suppress
ISG expression which is required for the establishment of an effective cellular antiviral response.
However, even though ISGs were first described as IFN-induced genes, some were subsequently
shown to be upregulated by viral infections in an IFN-independent manner though recognition of
viral components by PRRs and activation of constitutively expressed TFs such as IRF-3 and NFkappa B (Nakaya et al., 2001; Grandvaux et al., 2002; Peters et al., 2002; Elco et al., 2005;
Andersen et al., 2008; Basagoudanavar et al., 2011). Subsequent upregulation of additional TFs,
such as IRF-7, was also shown to play a role in the expression of some ISGs in infected cells
(Barnes et al., 2004). A previous report showed that IRF-7 and IRF-3 were important for IFN
production and protection against WNV (Fredericksen et al., 2004; Daffis et al., 2007; Daffis et
al., 2008).
Due to the high degree of homology between the ISRE and IRF binding element (IRF-E)
consensus sequences, the ISREs of some ISGs can be directly induced by either IRF-3 or IRF-7
(Lin et al., 2000; Morin et al., 2002; Schmid et al., 2010). In MEFs, Irf7 gene expression must
first be induced and then IRF-7 has to be activated before this TF can directly upregulate a subset
of ISGs (Barnes et al., 2004). In contrast, IRF-3 is a constitutively expressed protein that is
found in the cytoplasm of all cells in an inactive form. IRF-3 activation is mediated by
phosphorylation at multiple C terminal serine and threonine residues. Phosphorylation-induced
dimerization leads to nuclear translocation of IRF-3 in a complex with histone acetyltransferases
p300 and CREB-binding protein (CBP) (Yoneyama et al., 1998; Suhara et al., 2002; Fitzgerald et
al., 2003; Sharma et al., 2003). The results of an analysis of murine ISG expression during a
Newcastle disease virus (NDV) infection in IRF-3-/- MEFs led to the classification of ISGs such
as ISG15, ISG54, IP-10 and GBP as genes activated in an IRF-3-dependent manner and ISGs
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such as Oas1a and Irf7 as genes upregulated in an IRF-3-independent but IFN-dependent manner
through activation of the ISGF3 transcription factor complex (Nakaya et al., 2001). A more
recent analysis of ISG expression in IRF-3-/- MEFs infected with NDV confirmed that the
expression of the Oas1a and Irf7 did not depend on IRF-3 and showed that this was also the case
for the Oas1b and Irf1 genes (Andersen et al., 2008).
NF-kappa B exists in the cytoplasm in an inactive form in a complex with an inhibitory I kappa
B protein (Whiteside and Israel, 1997). Activation of the NF-kappa B pathway by viral infection
upregulates the expression of a specific subset of ISGs encoding cytokines and chemokines, such
as RANTES, TNF alpha and others, regulators of apoptosis and TFs, including A20, Irf1 and Irf2
and others (Pahl, 1999; Elco et al., 2005).
The murine 2'-5' oligoadenylate synthetase 1a (Oas1a) and Oas1b genes are ISGs that have
antiviral functions. Oas1a is an enzymatically active synthetase that upon binding to viral
dsRNA synthetizes 2'-5'-oligoadenylates (2-5A) from ATP which activate the latent
endonuclease RNase L. Activated RNaseL degrades both cellular and viral single-stranded
RNAs (Samuel, 2001). Oas1b is an inactive synthetase that mediates resistance to flavivirusinduced disease through an unknown RNase L independent mechanism (Scherbik et al., 2006).
Oas1b was also reported to inhibit in vitro Oas1a synthetase activity in a dose-dependent manner
(Elbahesh et al., 2011). IFN beta activation of Oas1a expression was shown to be STAT1- and
STAT2-dependent while that of Oas1b was STAT1-independent and STAT2-dependent
indicating that these two duplicated genes are differentially regulated by IFN beta (PulitPenaloza et al., 2012). WNV Eg101 infection in MEFs was previously reported to activate IFNbeta expression, induce STAT1 Tyr701 phosphorylation and upregulate the expression of Oas1a,
Oas1b as well as other ISGs including Irf7 and Irf1(Scherbik et al., 2006; Scherbik et al., 2007).
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However, whether the upregulation of these IRF-3-independent ISGs in WNV-infected cells is
mediated by IFN or by an alternative virus-activated pathway was not previously analyzed.
Although IFN beta expression is upregulated and STAT1 and STAT2 are phosphorylated in
WNV Eg101 infected cells, the present study showed that nuclear translocation of these TFs was
blocked. Consistent with this observation, no increase in the binding of either STAT1 or STAT2
to the Oas1a, Oas1b or Irf7 promoters or of STAT1 to the Irf1 promoter was observed. Each of
these genes was also upregulated by WNV Eg101 infection in control, STAT1-/-, STAT2-/- and
IFN alpha/beta R-/- MEFs indicating that these ISGs were not upregulated by the canonical type
1 IFN-mediated Jak-STAT pathway or by an alternative IFN alpha/beta R-mediated signaling
pathway. Oas1a, Oas1b and Irf7 were also upregulated in infected IRF-3-/-, IRF-7-/- MEFs and
initially in IRF-3/7-/- MEFs but not in infected IRF-3/9-/- MEFs suggesting the involvement of
IRF-9. Either IRF-3 or IRF-7 could enhance Oas1a and Oas1b upregulation at later times after
infection. Activation of Irf1 in infected MEFs did not depend on any of these IRFs. The IPS-1
signaling pathway was shown to be involved in the expression of all four ISGs. The data support
the existence of alternative mechanisms of ISG upregulation when the canonical type I IFN
pathway is blocked by a WNV infection.
RESULTS
3.1

The kinetics of IFN beta expression, secretion and signaling in WNV Eg101-infected
MEFs.

Previous studies reported increased STAT1 phosphorylation as well as increased expression of
many ISGs, including Oas1a, Oas1b, Irf1 and Irf7 in WNV Eg101-infected MEFs (Scherbik et
al., 2006; Scherbik et al., 2007). To determine whether ISG expression in WNV Eg101-infected
MEFs is temporally related to the induction of IFN beta, the kinetics of IFN beta expression in
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WNV Eg101 infected [multiplicity of infection (MOI) of 5], transformed C3H/He (tC3H/He)
MEFs were analyzed by real time qRT-PCR. IFN beta mRNA levels in tC3H/He MEFs were
elevated by 10 fold at 6 h, by 100 fold at 12 h and by more than 5000 fold at 24 and 48 h after
WNV Eg101 infection (Fig. 3.1A). The results obtained were similar to those previously
reported for infected primary C3H/He (pC3H/He) MEFs (Scherbik et al., 2006). Analysis of
extracellular IFN beta protein levels with an enzyme-linked immunosorbent assay (ELISA)
detected low levels of IFN beta at 16 h after WNV Eg101 infection of tC3H/He MEFs that
continued to increase through 48 h (Fig. 3.1B). At 48 h, 860 pg/ml of IFN beta were detected
which corresponds to about 730 International units/ml based on ELISA data obtained with
standard curves done on dilutions of an IFN beta sample of known unit concentration. Similar
IFN levels were previously reported for primary MEFs (Daffis et al., 2009).
The binding of IFN beta to its cell surface receptor results in activation of the Jak-STAT
signaling pathway and phosphorylation of STAT1 and STAT2. A previous study showed that
robust phosphorylation of STAT1 occurred in primary C3H/He MEFs after infection with WNV
Eg101 (Scherbik et al., 2007). To determine whether this was also the case in transformed MEFs,
activation of the Jak-STAT signaling pathway in tC3H/He MEFs by either IFN beta treatment or
WNV Eg101-infection were analyzed by Western blotting. Increased levels of both total and
phospho-STAT1 as well as of total and phospho-STAT2 were observed after a 3 h incubation of
cells with murine IFN beta (Fig. 3.1C). Upregulation of both total STAT1 and STAT2 levels was
also observed from 12 h through 48 h after WNV Eg101 infection. Low levels of phopshorylated
STAT1 (Tyr 701) were detected at 2, 6 and 12 h after infection, while robust phosphorylation
was seen at 24 and 48 h. Low levels of STAT2 phosphorylation (Tyr 690) were detected at 2
through 6 h and high levels were seen at 12 and 24 h after infection but not at 48 h. IRF-9
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Figure 3.1. IFN beta is produced by WNV Eg101-infected MEFs and induces
phosphorylation of STAT1 and STAT2. MEFs were mock-infected or infected with WNV
Eg101 at a MOI of 5 for the indicated times or treated with 1000 U/ml of murine IFN beta for
3h. (A) Total RNA from tC3H/He MEFs was extracted and IFN beta mRNA levels were
measured by real-time qRT-PCR. (B) Extracellular IFN beta protein levels in tC3H/He MEF
culture fluid was measured by ELISA. The values shown are averages from at least two
independent experiments performed in triplicate. The error bars represent SDM. (C) tC3H/He
cell lysates were analyzed by Western blotting using antibodies specific for the indicated
proteins. Actin was used as the loading control. The blots shown are representative of results
obtained from three independent experiments. (D) and (E) Comparison of ISG activation by IFN
beta in primary and transformed MEFs. Total RNA was extracted from (D) tC3H/He or (E)
pC3H/He MEFs infected with WNV Eg101 (MOI 5) for the indicated times, mock-infected or
treated with murine IFN beta (1000 U/ml) for 3h. The changes in the levels of Oas1a and Oas1b
mRNA were assessed by real-time qRT-PCR. Each experiment was repeated at least two times
in triplicate. The mRNA level of each gene was normalized to the level of GAPDH mRNA in
that sample and is shown as the fold change over the amount of mRNA in mock samples
expressed in relative quantification units (RQU). The error bars represent the calculated SEM (n
= 3) and are based on an RQMin/Max of the 95% confidence level.
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upregulation was detected as early as 6 h and was robust by 24 h after infection and also after a 3
h incubation with IFN beta. Viral NS3 protein levels were analyzed to estimate the efficiency of
viral infection. NS3 was detected by 12 h after infection and the levels increased at both 24 and
48 h (Fig 3.1C). The results indicated that upregulation of IFN beta production and its activation
of the Jak-STAT signaling pathway began early in WNV Eg101-infected MEFs and continued
throughout the infection. Although WNV Eg101 infection induced STAT1 and STAT2
phosphorylation in murine cells, infection of A549 (human) or MA104 (African green monkey)
cells with the this virus did not result in STAT phosphorylation (data not shown) similar to what
was previously reported for other lineage I WNV strain infections in primate cells (Laurent-Rolle
et al.; Liu et al., 2005; Keller et al., 2006).
3.2

Comparison of Oas1a, Oas1b, Irf7 and Irf1 expression levels in primary and
transformed C3H/He MEFs infected with WNV Eg101.

It was previously reported that transformed cells respond to IFN beta treatment but that the
levels of ISG upregulation are lower in these cells compared to those in primary cells (Bartee and
McFadden, 2009). Since both primary and transformed MEFs were used in this study, IFNinduced ISG upregulation in tC3H/He (Fig. 3.1D) and pC3H/He (Fig. 3.1E) MEFs was
compared. The four ISGs analyzed, Oas1a, Oas1b, Irf7 and Irf1, were upregulated in both types
of cells by IFN beta-treatment and WNV Eg101-infection. However, consistent with the previous
report, higher levels of ISG induction by both IFN and virus were observed in infected primary
MEFs than in transformed MEFs.
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3.3

Association of STAT1 and STAT2 with ISG promoters in WNV Eg101-infected
MEFs.

The observation that STAT1 and STAT2 were phosphorylated in WNV Eg101-infected MEFs
suggested that upregulation of the Oas1a, Oas1b, Irf7 and Irf1 genes might be mediated by the
canonical type I IFN pathway. The Oas1a and Oas1b promoters each contain a canonical ISRE
(Pulit-Penaloza et al., 2012), Irf7 contains an inverted ISRE (Ning et al., 2005; Schmid et al.,
2010) and the Irf1 promoter has a GAS element instead of an ISRE which is upregulated in IFNstimulated cells by a STAT1 dimer (Pine et al., 1994). STAT1 and STAT2 occupancy on the
Oas1a, Oas1b and Irf7 promoters and STAT1 occupancy on the Irf1 promoter in vivo was
analyzed with a chromatin immunoprecipitation (ChIP) assay done as described in Materials and
Methods using tC3H/He MEFs that were mock-infected, infected with WNV Eg101 (MOI of 5)
for 7, 16 or 24 h or treated with 1000 U/ml of murine IFN beta for 30 m. Briefly, in vivo
crosslinked DNA-protein complexes were immunoprecipitated using anti-STAT1, anti-STAT2
or a nonspecific IgG antibody. After reversing the crosslinks, immunoprecipitated DNA was
purified and quantified by real-time qPCR. An increase in STAT1 (Fig. 3.2A) and STAT2 (Fig.
3.2B) promoter binding compared to that in untreated cells was detected for Oas1a, Oas1b and
Irf7 in cells treated with IFN beta. In contrast, no significant increase in either STAT1 or
STAT2 promoter binding compared to mock infected cells was detected in cells infected with
WNV Eg101 for 7, 16 or 24 h. An increase in STAT1 binding to the Irf1 promoter was observed
in cells treated with IFN but not in cells infected with WNV Eg101. These results suggested that
the nuclear translocation of phosphorylated STAT1 and STAT2 was blocked in the WNV
Eg101-infected cells. To test this hypothesis, the kinetics of STAT1 and STAT2 nuclear
translocation in tC3H/He MEFs infected with WNV Eg101 (MOI of 5) were analyzed by
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Figure 3.2. STAT1 and STAT2 translocation to the nucleus is inhibited in WNV Eg101infected MEFs. A chromatin immunoprecipitation assay (ChIP) assessed binding (A) of STAT1
to the Oas1a, Oas1b, Irf7 and Irf1 promoters and (B) of STAT2 to the Oas1a, Oas1b and Irf7
promoters in vivo. The amount of precipitated Oas1a and Oas1b promoter DNA was quantified
by real-time qPCR with promoter specific primers and fluorogenic TaqMan FAM/MGB probes.
Nonspecific IgG antibody was used as a negative control and averaged values are shown. The
averages from at least two independent experiments performed in triplicate were plotted and the
error bars show SDM. (C) tC3H/He MEFs were infected with WNV at a MOI of 5 for the
indicated times. (D) tC3H/He MEFs were incubated with 1000 U/ml of IFN beta for 30 m at
different times after WNV Eg101 infection. Cellular localization was analyzed by laser scanning
confocal microscopy. Nuclei were stained with Hoescht dye (blue), STAT2 was detected using
anti-STAT2 antibody (green) and infected cells were detected with anti-dsRNA antibody (red).
The results are representative of two independent experiments. (E) Quantification of the results
in panels A and B. The pixel intensity in the representative area in nucleus was measured and
divided by the pixel intensity of the same size area in the cytoplasm. The measurement was done
for 20 cells at each time after infection and each treatment. The mean values were plotted and
error bars indicate SDM (n = 20). (F) t129 MEFs were mock treated, treated with IFN beta (500
U/ml) for 30 m or infected with WNV Eg101 at a MOI of 5 for 16 or 24 h. Whole cell lysates
were separated into cytoplasmic and nuclear fractions and analyzed by Western blotting using
antibodies specific for STAT1, STAT2 or histone 3 (H3). H3 was used as a control nuclear
protein. The blots shown are representative of the results obtained from two independent
experiments.
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confocal microscopy. Robust STAT2 nuclear translocation, as indicated by STAT2 accumulation
in the nucleus, was detected in IFN beta-treated cells (Fig. 3.2D top row) but not in mock-treated
cells or cells infected with WNV Eg101 for 8, 16, 24, 32 and 48 h (Fig. 3.2C and E). Similar
confocal microscopy results were also observed for STAT1 (data not shown). Western blotting
of cytoplasmic and nuclear cell fractions from infected and IFN-treated t129 MEFs cells
confirmed the lack of STAT1 and STAT2 nuclear accumulation in infected MEFs of a different
genetic background (Fig. 3.2F). Similar Western results were obtained with tC3H/He MEFs
(data not shown). To test whether a WNV Eg101 infection could block STAT2 nuclear
translocation mediated by the addition of exogenous IFN beta, tC3H/He MEFs infected with
WNV Eg101 for 8, 16, 24, 32 or 48 h were incubated with murine IFN beta (1000 U/ml) for 30
m before fixing the cells. In mock-infected cells and cells infected for 8 h (a time when viral
dsRNA is not yet detectable by immunofluorescence; Fig. 3.2C second row), the addition of IFN
beta resulted in detectable STAT2 nuclear translocation (Fig. 3.2D second row). In contrast,
nuclear translocation of STAT2 was not observed when IFN beta was added to cells infected for
16, 24, 32 or 48 h (Fig. 3.2D). The results indicate that similar to other lineage I WNV strains
studied (Keller et al., 2006; Laurent-Rolle et al., 2010), a WNV Eg101 infection can block
STAT1 and STAT2 nuclear translocation.

3.4

Expression of ISGs in WNV Eg101-infected tSTAT1-/- and tSTAT2-/- MEFs.

The ChIP and nuclear translocation assay results indicated that upregulation of Oas1a, Oas1b,
Irf7 and Irf1 gene expression in WNV Eg101-infected MEFs was mediated in a STAT1- and
STAT2-independent manner. As an additional means of confirming this, the expression of these
four ISGs genes was analyzed by real time qRT-PCR in tSTAT1-/- and tSTAT2-/- MEFs and
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Figure 3.3. Oas1a, Oas1b, Irf7 and Irf1 gene expression is induced in WNV Eg101-infcted
tSTAT1-/- and tSTAT2-/- MEFs. Fold induction of (A) Oas1a, (B) Oas1b, (C) Irf7 and (D) Irf1
mRNA mRNA expression levels in t129, tSTAT1-/- and tSTAT2-/- MEF cell lines was
measured by real-time qRT-PCR. Because the expression of Oas1a was not detected (ND) in the
mock-treated tSTAT1-/- and tSTAT2-/- MEFs, the expression of Oas1a was normalized to the 8
h WNV Eg101 sample. Each experiment was repeated at least two times in triplicate. The
mRNA level of each gene was normalized to the level of GAPDH mRNA in that sample and is
shown as the fold change over the amount of mRNA in mock samples expressed in RQU. The
error bars represent the calculated SEM (n = 3) and are based on an RQMin/Max of the 95%
confidence level. (E) Culture fluid samples harvested at the indicated times after infection were
titered for infectivity by plaque assay. Each data point is the average of duplicate titrations from
at least two experiments. Error bars indicate SDM. (F) t129 and tSTAT2-/- MEF cell lysates
were analyzed by Western blotting using antibodies specific for the indicated proteins. Actin was
used as the loading control. The blots shown are representative of results obtained from two
independent experiments.
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matched control wild type t129 MEFs that were mock-infected, infected with WNV Eg101 (MOI
of 5) or treated with murine IFN beta (1000 U/ml) for 3 h. A 10-fold or greater increase in
Oas1a, Oas1b and Irf7 mRNA levels was observed in wild type t129 MEFs stimulated with IFN
beta for 3 h or infected with WNV Eg101 for 32 h (Fig. 3.3A, B and C). Consistent with
previous observations (Ousman et al., 2005; Pulit-Penaloza et al., 2012), no upregulation of
Oas1a after stimulation with IFN beta was observed in either tSTAT1-/- or tSTAT2-/- MEFs
(Fig. 3.3A), while Oas1b (Fig. 3.3B) and Irf7 (Fig.3.3C) upregulation was observed in tSTAT1-/but not in tSTAT2-/- MEFs. In contrast to the tSTAT1- and tSTAT2-dependence of Oas1a
upregulation by IFN beta, Oas1a mRNA was detected at 8 h and increased by more than 50 fold
by 32 h after WNV infection in both tSTAT1-/- and tSTAT2-/- MEFs (Fig. 3.3A). Oas1b mRNA
levels increased by about 3-fold at 24 h and by about 300-fold at 32 h after infection in tSTAT1/- MEFs and by about 3-fold at 24 h and by about 20-fold at 32 h after infection in tSTAT2-/MEFs. Although the fold increase observed for Oas1b expression in infected tSTAT2-/- MEFs
was lower than that in tSTAT1-/- MEFs, it was still higher than the 10-fold increase observed in
infected control t129 MEFs. In both tSTAT1-/- and tSTAT2-/- MEFs, Irf7 mRNA levels
increased by about 2-fold by 16 h after infection. Although a 60-fold increase in Irf7 expression
was observed in both wild type t129 and tSTAT1-/- MEFs by 32 h after infection, only a 7-fold
increase in Irf7 mRNA levels was observed in infected tSTAT2-/- MEFs by this time. No
upregulation of Irf-1 after stimulation with IFN beta was observed in either tSTAT1-/- or
tSTAT2-/- MEFs similar to what was observed with Oas1a. A significant increase in Irf1 mRNA
levels was observed in both tSTAT1-/- and tSTAT2-/- MEFs at 24 h after infection but these
levels were lower compared to those in the control t129 MEFs. However, by 32 h, the levels of
Irf1 mRNA were the same in the control and both types of knockout cells (Fig. 3.3D). Virus
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yields from tSTAT1-/- and tSTAT2-/- MEFs were initially higher than those from t129 control
cells but all of these cell types produced a peak titer of about 107 PFU/ml by 32 h after infection
(Fig. 3.3E).

IRF-3 was previously reported to be activated by 16 h after a WNV Eg101 infection in pC3H/He
MEFs indicating virus activation of cytoplasmic PRRs (Scherbik et al., 2007). The activation of
IRF-3 was compared in t129 and tSTAT2-/- MEFs by Western blotting using antibodies against
total IRF-3 and IRF-3 phosphorylated on Ser396. Phosphorylated IRF-3 was detected at 24 and
32 h after WNV Eg101 infection in control t129 MEFs and at 16, 24 and 32 h in tSTAT2 -/MEFs (Fig. 3.3F). Although earlier and more robust activation of IRF-3 was observed in
tSTAT2-/- MEFs compared to wild type MEFs the level of ISG upregulation was lower in these
cells.

3.5

Analysis of the dependence of Oas1a, Oas1b, Irf7 and Irf1 expression in WNV Eg101infected MEFs on alternative signaling pathways activated by the IFN alpha/beta
receptor.

In addition to activation of the Jak-STAT pathway, type I IFN binding to the IFN alpha/beta R
has also been reported to activate the PI3K (Kaur et al., 2005) and p38 mitogen-activated protein
kinase (MAPK) signaling pathways (Katsoulidis et al., 2005). Although the results described
above indicate that the Jak-STAT pathway is not involved in the upregulation of the ISGs
analyzed in WNV Eg101-infected MEFs, the involvement of an alternative signaling cascade
induced by type I IFN had not been ruled out. To determine whether the upregulation of the
Oas1a, Oas1b, Irf7 and Irf1 genes in WNV Eg101-infected MEFs was mediated by type 1 IFN
alpha/beta R signaling through an alternative pathway, the expression of these genes was
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alpha- or IFN beta-treated pIFN alpha/beta R-/- cells, Oas1a expression in these cells was
normalized to the 8 h WNV Eg101 sample. Each experiment was repeated at least two times in
triplicate. The error bars represent the calculated SEM (n = 3) and are based on an RQMin/Max of
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at least two experiments. Error bars indicate SDM.
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analyzed in pIFN alpha/beta R -/- MEFs infected with WNV Eg101 (MOI of 5) by real time
qRT-PCR. All four of the ISGs were upregulated in control p129 MEFs treated with either
universal type I IFN (human IFN alpha) or murine IFN beta as well as in control MEFs infected
with WNV Eg101 (Fig. 3.4A, B, C and D). Because primary 129 MEFs were used for these
experiments, the level of gene upregulation was higher compared to that in the transformed 129
MEFs used for the experiments shown in Fig. 3.3. As expected, no increase in Oas1a, Oas1b,
Irf7 or Irf1 expression was observed in pIFN alpha/beta R -/- MEFs after IFN alpha or IFN beta
treatment. Consistent with the results obtained with tSTAT1-/- and tSTAT2-/- MEFs, basal
Oas1a expression was also not detected in mock-infected pIFN alpha/beta R -/- MEFs. In
contrast to the lack of upregulation by IFN beta, a significant increase in Oas1a, Oas1b, Irf7 and
Irf1 gene expression was observed in pIFN alpha/beta R -/- MEFs infected with WNV Eg101 for
16, 24 or 32 h. The upregulation of the Oas1a and Oas1b genes in the infected pIFN alpha/beta R
-/- MEFs was delayed compared to that in the control MEFs; however, by 24 h after infection the
mRNA levels for both these genes were comparable to those in wild type MEFs. The activation
of Irf7 was delayed and although Irf7 mRNA levels increased by about 50-fold by 32 h after
infection in pIFN alpha/beta R -/- MEFs, the maximal upregulation was 20 times less efficient
compared to that in the wild type cells (Fig. 3.4C). Irf1 expression in the IFN receptor knockout
cells was also delayed and less efficient as compared to that observed in the wild type cells (Fig.
3.4D). Similar to what was previously reported for WNV NY 2000 (Daffis et al., 2009), WNV
Eg101 replicated more efficiently in IFN alpha/beta R-/- MEFs than in the control MEFs (Fig.
3.4E).
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3.6

Analysis of the transcription factors regulating ISG expression during WNV Eg101
infection.

To further investigate the role of IRF-3 in upregulating the four ISGs analyzed in WNV Eg101infected MEFs, pIRF-3-/- and matched wild type pC57/BL6 MEFs were infected with WNV
Eg101 (MOI 5) and the Oas1a, Oas1b, Irf7 and Irf1 mRNA levels were measured by real time
qRT-PCR. The Oas1a, Oas1b and Irf7 genes were efficiently upregulated in IRF-3-/- and control
cells by both IFN beta and WNV infection (Fig. 3.5A, B and C). Similarly, the Oas1a and Oas1b
genes were efficiently upregulated by IFN beta and WNV infection in pIRF-7-/- MEFs. These
data suggest that neither IRF-3 nor IRF-7 alone is critical for the upregulation these ISGs in
WNV Eg101-infected MEFs. The more efficient upregulation of the tested ISG observed in cells
deficient in IRF-3 or IRF-7 compared to the wild type control cells suggested the possibility that
these two transcription factors may be involved in a negative feedback mechanism of ISG
expression. Since the combination of IRF-3 and IRF-7 was previously reported to be required for
robust production of type I IFN as well as for the induction of ISGs such as ISG54, ISG49 and
RIG-I in MEFs infected with WNV NY 2000 (Daffis et al., 2009), the induction of Oas1a and
Oas1b expression was also analyzed in pIRF-3/7-/- MEFs. Although Oas1a and Oas1b
expression was upregulated to similar levels in control and pIRF-3/7-/- MEFs at 8 and 16 h after
WNV Eg101 infection, a decrease in Oas1a and Oas1b mRNA levels compared to the control
cells was observed at 24 and 32 h after infection suggesting that at least one of these TFs is
needed to enhance the upregulation of these ISGs in infected cells at later times of infection. Irf1
upregulation by WNV Eg101 infection was similar in pIRF-3/7-/- and control MEFs (Fig. 3.5D).
Irf9 mRNA levels were also assessed in pIRF-3/7-/- MEFs. Irf9 was upregulated to similar levels
in WNV Eg101-infected control and pIRF-3/7-/- MEFs (Fig. 3.5E). WNV Eg101 replicated as
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Figure 3.5. The expression of Oas1a and Oas1b but not Irf1 and Irf9 is reduced in IRF-3/7/- MEFs. Fold increase in (A) Oas1a, (B) Oas1b, (C) Irf7 mRNA, (D) Irf9 and (E) Irf1
expression levels in pC57BL/6, pIRF-3-/-, pIRF-7-/- and pIRF-3/7-/- MEFs was measured by
real-time qRT-PCR. Each experiment was repeated at least two times in triplicate. The mRNA
level of each gene was normalized to the level of GAPDH mRNA in that sample and is shown as
the fold change over the amount of mRNA in mock samples expressed in RQU. The error bars
represent the calculated SEM (n = 3) and are based on an RQMin/Max of the 95% confidence level.
(F) Culture fluid harvested at the indicated times after infection was titered for infectivity by
plaque assay. Each data point is the average of duplicate titrations from at least two experiments.
Error bars indicate SDM.
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Figure 3.6. Irf1 but not Oas1a, Oas1b and Irf7, is upregulated in IRF-3/9-/- MEFs infected
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expression levels in C57BL/6 and IRF-3/9/- MEFs was measured by real-time qRT-PCR. Each
experiment was repeated at least two times in triplicate. The mRNA level of each gene was
normalized to the level of GAPDH mRNA in that sample and is shown as the fold change over
the amount of mRNA in mock samples expressed in RQUs. The error bars represent the
calculated SEM (n = 3) and are based on an RQMin/Max of the 95% confidence level. (E) Culture
fluid harvested at the indicated times after infection was titered for infectivity by plaque assay.
Each data point is the average of duplicate titrations from at least two experiments. Error bars
indicate SDM.
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efficiently in pIRF-3-/- and pIRF-7-/- MEFs as in wild type cells but the pIRF-3/7-/- MEFs
produced higher yields of virus (Fig. 3.5F).

The induction of Irf7, Irf1 and Oas1a gene expression by poly(I:C) was previously shown to be
blocked in IRF-3/9-/- MEFs (DeWitte-Orr et al., 2009). To test whether the expression of these
ISGs is induced by WNV Eg101 infection in the absence of IRF-3 and IRF-9, pIRF-3/9-/- MEFs
were infected with WNV Eg101 (MOI 5) for 8, 16, 24 or 32 h and Oas1a, Oas1b, Irf7 and Irf1
mRNA levels were measured by real time qRT-PCR. No significant upregulation of Oas1a,
Oas1b or Irf7 expression was observed in these knockout cells (Fig. 3.6A, B and C). Since IRF-3
was shown not to be required for ISG upregulation in WNV infected MEFs, the data obtained
with the pIRF-3/9-/- MEFs suggested that IRF-9 was required. Irf1 expression was upregulated
in pIRF-3/-9-/- MEFs to the same or higher levels than in control MEFs (Fig. 3.6D) indicating
that this gene is upregulated in infected cells by a different set of TFs than those regulating the
Oas1a, Oas1b and Irf7 genes. Analysis of the WNV Eg101 yields produced by control and pIRF3/9-/- MEFs indicated that virus replication was more efficient in the pIRF-3/9-/- MEFs (Fig.
3.6E).
Previous studies showed that a WNV infection is sensed by the cytoplasmic RNA sensors RIG-I
and MDA5 (Fredericksen and Gale, 2006; Fredericksen et al., 2008). Upon recognition of viral
RNA RIG-I and MDA5 interact through their caspase activation and recruitment domains
(CARDs) with adaptor molecule promoter-stimulating factor (IPS-I) (Kato et al., 2008; Takeuchi
and Akira, 2008). A previous study showed that IPS-1 is required for the activation of IRF-3 and
the IRF-3 target genes, ISG54 and ISG56, in WNV infected cells (Fredericksen et al., 2008;
Suthar et al., 2010). To assess the roles of RIG-I, MDA5 and IPS-1 in the induction of IRF-3
independent ISG upregulation, pRIG-I-/-, pMDA5-/- and pIPS-1-/- MEFs were mock treated,
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Figure 3.7. IPS-1 is involved in the upregulation of Oas1a, Oas1b, Irf7 and Irf1 in MEFs
infected with WNV Eg101. Fold increase in (A) Oas1a, (B) Oas1b, (C) Irf7, (D) Irf1 and (E)
IFN beta mRNA expression levels in pC57BL/6, pRIG-I-/-, pMDA5-/- and pIPS-1-/- MEFs was
measured by real-time qRT-PCR. Each experiment was repeated at least twice in triplicate. The
mRNA level of each gene was normalized to the level of GAPDH mRNA in that sample and is
shown as the fold change over the amount of mRNA in mock samples expressed in RQUs. The
error bars represent the calculated SEM (n = 3) and are based on an RQMin/Max of the 95%
confidence level. (F) Culture fluid harvested at the indicated times after infection was titered for
infectivity by plaque assay. Each data point is the average of duplicate titrations from at least two
experiments. Error bars indicate SDM.
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treated with 1000 U/ml of IFN beta or infected with WNV Eg101 at a MOI of 5 and the Oas1a,
Oas1b, Irf7 and Irf1 mRNA levels were measured by real time qRT-PCR (Fig. 3.7A, B, C and
D). Although the level of Oas1a, Oas1b, Irf7 and Irf1 upregulation was similar in WNV infected
RIG-I-/- and control MEFs, the expression of these ISGs in infected MDA5-/- MEFs was lower
suggesting that MDA5 signaling plays a more important role during WNV infection. It was
previously reported that RIG-I and MDA5 play different but redundant roles in the activation of
IRF-3 and IRF-3 dependent genes in WNV infected cells (Fredericksen et al., 2008; Loo et al.,
2008). At 8 h after infection, Oas1a was upregulated to similar levels in control and IPS-1-/MEFs while the upregulation of Oas1b and Irf7 was lower in infected IPS-1-/- MEFs than in
control cells. However, the mRNA levels of all three of these ISGs decreased progressively at
later times after infection. No significant upregulation of Irf1 was observed in infected IPS-1-/MEFs at 8h. A small increase in Irf1 upregulation was observed at 16 h but the mRNA levels
decreased at later times. The data indicate that IPS-1 is only partially involved in the initial
induction of IRF-3-independent ISGs in WNV infected cells but is required for gene expression
at later times after infection. Only minimal upregulation of the IFN beta gene was observed in
either IFN beta or WNV infected pIPS-1-/- MEFs (Fig. 3.7E). Higher WNV Eg101 yields were
produced by IPS-1-/- MEFs than by RIG-I-/-, MDA5-/- or wild type MEFs (Fig. 3.7F).
DISCUSSION
Activation of ISGs by type 1 IFN is mediated by the ISGF3 TF complex composed of STAT1,
STAT2 and IRF-9. STAT1 and STAT2 proteins primarily reside in the cytoplasm and the
formation and nuclear translocation of the ISGF3 complex depends on IFN-mediated
phosphorylation of STAT1 on Tyr701 and STAT2 on Tyr690 (Schindler et al., 1992; Shuai et
al., 1992; Qureshi et al., 1996). Most viruses, including flaviviruses, have evolved mechanisms
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to suppress the type 1 IFN pathway. The lineage I WNV strains TX02 and NY99 inhibit STAT1
and STAT2 nuclear translocation by blocking phosphorylation of these proteins in primate cells
and the WNV NY99 NS5 protein was shown to mediate this suppression (Keller et al., 2006;
Laurent-Rolle et al., 2010). In contrast, the attenuated lineage I strain, Kunjin, is a poor
suppressor of STAT1 phosphorylation due to a single NS5 mutation, Phe653Ser (Laurent-Rolle
et al., 2010). Eg101 and NY99 are closely related lineage I viruses but Eg101 it is less
neuroinvasive (Beasley et al., 2002). The WNV Eg101 NS5 has a Phe at position 653 and blocks
STAT phosphorylation in primate cells (Scherbik and Brinton, unpublished data). In contrast,
WNV Eg101 infections did not block STAT1 phosphorylation at Tyr701 or STAT2
phosphorylation of Tyr690 in MEFs. A decrease in STAT2 phosphorylation was only observed
at 48 h. These results indicate host species specific differences in the ability of WNV to suppress
STAT phosphorylation. How a WNV Eg101 infection prevents nuclear translocation of phosphoSTAT1 and phospho-STAT2 in MEFs is currently under investigation. The dengue virus NS5
protein was previously reported to bind to and target human STAT2 for degradation but was not
able to mediate the degradation of murine STAT2 (Ashour et al., 2010). No evidence of either
STAT1 or STAT2 degradation was observed in WNV Eg101-infected MEFs.

Activation of the Oas1a, Oas1b, Irf7 and Irf1 genes was previously reported to be IRF-3independent (Nakaya et al., 2001; Andersen et al., 2008) and the Oas1a and Irf7 genes were
reported to be activated only by canonical type I IFN signaling (Nakaya et al., 2001). Data from
the present study indicated that upregulation of Oas1a, Oas1b, Irf7 and Irf1 occurred by a
STAT1-, STAT2- and type I IFN-independent regulatory mechanism in WNV Eg101-infected
MEFs. Although the activation of IRF factors, such as IRF-3 and IRF-7, by viral infections was
previously reported to mediate IFN-independent upregulation of subsets of ISGs, the Oas1a,
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Oas1b, Irf7 and Irf1genes were efficiently upregulated by WNV Eg101 infection in IRF-3-/MEFs and the Oas1a, Oas1b, and Irf1 genes were efficiently activated in IRF-7-/- MEFs
indicating that neither IRF-3 nor IRF-7 alone was sufficient to induce upregulation of these
genes in infected MEFs. A previous study done with WNV NY 2000-infected IRF-3/7 -/- MEFs
reported that both IRF-3 and IRF-7 were necessary for production of type I IFN and induction of
ISGs such as ISG54, ISG49 and RIG-I (Daffis et al., 2009). We also found only a very low level
of IFN beta gene upregulation in WNV Eg101-infected IRF-3/7 -/- MEFs; at 32 h after infection,
there was a 27 fold increase in IFN beta mRNA levels compared to an 8000 fold increase in wild
type MEFs (data not shown). In contrast, efficient induction of the Oas1a, Oas1b, Irf7 and Irf1
genes was observed in IRF-3/7 -/- MEFs infected for 8 and 16 h with WNV Eg101. However,
the absence of both IRF-3 and IRF-7 reduced the levels of Oas1a and Oas1b expression at later
times of infection suggesting that at least one of these IRFs is needed to enhance and sustain the
upregulation of these two ISGs. No Oas1a and Oas1b upregulation was observed in IRF-3/9-/MEFs and the expression of Irf7 was also not upregulated in these cells. These observations
together with the observation that Irf9 was upregulated in infected IRF-3/7-/- MEFs suggest the
possibility that IRF-9 is involved in the initial upregulation of these ISGs in WNV Eg101infected cells. Since IRF-9 cannot transactivate gene expression alone (Kraus et al., 2003), it
must interact with additional partners to active ISG expression in MEFs infected with WNV
Eg101. However, it is not currently known whether IRF-9 can form complexes with as yet
unidentified TF(s) and whether IRF-9 can interact with IRF-3 and/or IRF-7 to upregulate a
subset of ISGs in WNV Eg101-infected MEFs.

IRF-1 was originally described as a TF involved in the induction of the IFN-alpha and IFN-beta
genes (Miyamoto et al., 1988). However, it can also upregulate the expression of some ISGs in
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an IFN-independent manner (Schoggins et al., 2011). Overexpression of Irf1 was recently shown
to inhibit the replication of WNV, dengue virus, yellow fever virus, hepatitis C virus,
Chikungunya virus, Venezuelan encephalitis virus and human immunodeficiency virus I
(Schoggins et al., 2011). One of the IRF-1 target genes, viperin, (Stirnweiss et al., 2010) was
reported to inhibit both WNV and dengue virus infections (Jiang et al., 2010). In a previous
study from our lab, the kinetics of upregulation of multiple ISGs in primary C3H/He MEFs
infected with WNV Eg101 was analyzed (Scherbik et al., 2007). ISGs such as Oas1a, Oas1b and
Irf7 were efficiently upregulated by WNV Eg101 at early times after infection while the
upregulation of a subset of ISGS including Irf1 was delayed. The Irf1 gene promoter contains a
GAS element instead of an ISRE and upregulation of this gene by type I and type II IFNs is
dependent on STAT1 dimers rather than the ISGF3 TF complex (Pine et al., 1994). The murine
Irf1 gene was previously reported to be activated in an IRF-3-independent manner (Andersen et
al., 2008). However, another study reported that Irf1 upregulation by poly(I:C) was blocked in
IRF-3/9-/- MEFs (DeWitte-Orr et al., 2009). The results of the present study indicate that the
upregulation of Irf1 gene expression in WNV Eg101-infected MEFs is mediated in an IRF-3-,
IRF-9- and IRF-7-independent manner. An Irf1 promoter analysis predicted the presence of NFkappa B binding sites (Harada et al., 1994; Pine et al., 1994) and Irf1 gene expression was
previously reported to be induced by this TF (Pahl, 1999). NF-kappa B is activated by a WNV
Eg101-infection in MEFs (Scherbik et al., unpublished results) and the involvement of NF-kappa
B components in regulating Irf1 upregulation in infected cells is currently under investigation.
During a WNV infection, viral RNA is recognized by RIG-I and MDA5 cytoplasmic sensors
(Fredericksen et al., 2008) which signal through the IPS-1 adaptor molecule to activate IRF-3
leading to the induction of IFN and IRF-3-dependent gene expression (Fredericksen et al., 2008;
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Daffis et al., 2009; Suthar et al., 2010). The results of the present study showed that lack of
MDA5 but not of of RIG-I resulted in reduction in the upregulation of Oas1a, Oas1b, Irf7 and
Irf1 suggesting that MDA5 may be functionally more important for the upregulation of these
genes. In addition, the results of this study showed that the initial upregulation of Oas1a, Oas1b
and Irf7 but not of Irf1 in WNV Eg101infected MEFs is only partially dependent on IPS-1 since
the mRNA levels of these genes were upregulated in IPS-1 deficient cells at 8 h after infection.
The lack of induction of IFN beta gene expression at 8 h after infection in IPS-1-/- MEFs
confirmed that the upregulation of these genes was independent of IFN-beta. The mechanism by
which the initial IFN- and IPS-1-independent upregulation of a subset of ISGs occurs is currently
not known. Early induction of ISGs may be due to activation of signaling pathways activated by
WNV entry. The existence of such a response to virus particle entry was previously reported and
shown to be IFN-, TLR- and RIG-I independent (Paladino et al., 2006). The interaction of the
fusion peptides of enveloped viruses with cellular membranes were also shown to activate
several cell transduction pathways leading to early activation of ISGs by AP-1 and NF-kappa B
(Vitiello et al., 2010). However, IPS-1 is required for ISG expression at later times of infection.

The higher viral loads in tissues and increased mortality observed with WNV NY99-infected
IFN alpha/beta R-/- and IFN beta-/- mice indicate the importance of the type I IFN response for
host protection (Samuel and Diamond, 2005; Lazear et al., 2011). Type I IFN secreted by
infected cells induces an antiviral state in uninfected cells through the induction of ISGs and this
reduces viral spread. The upregulation of ISGs by IFN-independent mechanisms in infected cells
would be expected to reduce virus yields even though canonical IFN signaling was blocked by
the infection in these cells. It was previously shown that IRF-3-dependent ISGs could be
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upregulated in WNV-infected cells and experiments in IRF-3-/- mice indicated that IRF-3
protected mice by both IFN-dependent and IFN-independent mechanisms (Fredericksen et al.,
2004; Daffis et al., 2007). IRF-7 was shown to protect mice primarily through the induction of
IFN alpha (Daffis et al., 2008). The data obtained in the present study indicate that there are
additional mechanisms of IFN-independent ISG upregulation for subsets of ISGs in infected
MEFs and that IFN-independent ISG upregulation is more complex than previously appreciated.
The data also suggest that IRF-9 may also be involved in both IFN-dependent as well as IFNindependent activation complexes for some ISGs.
MATERIALS AND METHODS
3.7

Cells and viruses.

SV40-T antigen transformed C3H/He (tC3H/He) MEFs were grown in minimal essential
medium (MEM) supplemented with 5% fetal bovine serum (FBS) and 10 µg/ml gentamicin.
Primary C3H/He MEFs (pC3H/He), pIRF-3-/-, pIRF-7-/- and pC57BL/6 MEFs (provided by
Michael Diamond, Washington University School of Medicine, ST. Louis, Missouri) were
grown in DMEM supplemented with 10% FBS and 10 µg/ml gentamicin. pIRF-3/7-/- MEFs
(provided by Michael Diamond, Washington University School of Medicine, ST. Louis,
Missouri) were grown DMEM supplemented with 15% FBS and 1% PenStrep (Gibco).
t129/SvEv, tSTAT1-/- and tSTAT2-/- MEF lines (provided by Christian Schindler, Columbia
University, New York, NY) were grown in MEM supplemented with 10% FBS and 1%
PenStrep. p129 MEFs and pIFN alpha/beta R -/- MEFs (provided by Herbert Virgin, Washington
University School of Medicine, St. Louis, MO) were grown in DMEM supplemented with 10%
FBS and 1% PenStrep. IRF-3/9-/- MEFs (provided by Karen Mossman, McMaster University,
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Hamilton, Ontario, Canada) were grown in MEM alpha supplemented with 10% FBS and 1%
PenStrep. All cell cultures were grown at 37°C in a 5% CO2 atmosphere.

A stock of lineage I WNV strain Eg101 was prepared by infecting BHK cells (Vaheri et al.,
1965) grown in MEM supplemented with 5% FBS and 10 µg/ml gentamicin at a MOI of 0.1 and
harvesting culture fluid 32 h after infection, a time when the infected cell monolayer was still
intact. Clarified culture fluid was aliquoted and stored at –80°C. The titer of the stock virus was ~
1 x 108 PFU/ml.
3.8

ELISA.

Cell culture fluid was collected at various times after WNV Eg101 infection and the levels of
secreted IFN beta protein in these samples were measured by a capture ELISA according to the
manufacturer's instructions (PBL Biomedical Laboratories, NJ) using a standard curve prepared
by titrating a known concentration of recombinant murine IFN beta.
3.9

ChIP.

Confluent tC3H/He monolayers were mock-infected, infected with WNV Eg101 at a MOI 5 for
7, 16 or 24 h or treated with 1000 U/ml of murine IFN beta for 3 h. The ChIP assay was done as
previously described (Pulit-Penaloza et al., 2012). Isolated DNA was analyzed by real-time PCR
using probes and primers designed to span the proximal Oas1a and Oas1b promoters. The
sequences

of

the

primers

were:

GGATCCTAAGAAAGCTCAGACTTCA-3',

Oas1a
Oas1a

forward
reverse

primer
primer

5'5'-

CCCGGCAGCCAATGG-3', Oas1b forward primer 5'- GAAGCCCTAACGCCATTGG-3',
Oas1b

reverse

primer

5'-AGGGCGCGGATATGCA-3',

Irf7

forward

primer

5'-
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CCTGCCTTGTCCCAATGTG-3'
ACACCCGACCCTTACTCAGATC-3'

and

Irf7
and

Irf1

reverse
forward

primer
primer

5'5'-

CCTTCGCCGCTTAGCTCTAC-3' and Irf1 reverse primer 5'-CCCACTCGGCCTCATCATT-3'.
The sequence of the FAM-MGB Oas1a probe was 5'-TGGAAGTGTGGGAAAGGTCTTT-3',
that of the Oas1b probe was 5'-CGGGCCTGGATGAT-3' and that of the Irf7 probe was 5'TTTCCTGAAGAGGTCCTG-3' and that of Irf-1 probe was 5'-ACAGCCTGATTTCC-3'. To
obtain standard curves, known amounts of Oas1a, Oas1b and Irf7 and Irf1 promoter DNA cloned
into a TOPO-XL vector (Invitrogen) were titrated and assayed by real-time quantitative PCR
(qPCR) using a FastStart Universal Probe Master (ROX) kit (Roche Applied Science) according
to the manufacturer's protocol. To quantify the immunoprecipitated DNA, standard curves were
independently generated at the same time as the immunoprecipitated DNA samples by qPCR and
the value of the fold change over the value obtained with a mock-infected sample was calculated.
The average values from at least two independent experiments were plotted. Error bars represent
SDM.
3.10 Quantification of mRNA levels.
Real-time quantitative reverse transcription-PCR (qRT-PCR) analyses of mouse Oas1a and
Oas1b gene expression were performed using a 50 µl reaction mixture containing 500 ng of total
cellular RNA, the primer pair (1 µM), and the probe (0.2 µM) and an Applied Biosystems 7500
Sequence Detection System. Applied Biosystems Assays-on-Demand 20x primer and fluorogenic
TaqMan FAM/MGB probe mixes Mn00836412_m1 for Oas1a, Mn00449297_m1 for Oas1b,
Mn00516788_m1 for Ifr7 and Mn01288580_m1 for Irf1 were used. Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA was used as an endogenous control for each sample and was
detected using TaqMan mouse GAPDH primers and probe (Applied Biosystems). One-step RT-
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PCR was performed for each target gene and for the endogenous control in a singleplex format
using 200 ng of RNA and the TaqMan One-Step RT-PCR Master Mix Reagent Kit (Applied
Biosystems). The cycling parameters were as follows: reverse transcription at 48°C for 30 m,
AmpliTaq activation at 95°C for 10 m, denaturation at 95°C for 15 s, and annealing/extension at
60°C for 1 m (cycle repeated 40 times). Each experiment was repeated at least two times in
triplicate. Triplicate Ct values were analyzed with Microsoft Excel using the comparative Ct
(∆∆Ct) method of the SDS Applied Biosystems software which also applied statistical analysis
to the data (TINV test in Microsoft Excel). The values were normalized to those for GAPDH and
presented as the relative fold change compared to the uninfected calibrator sample in relative
quantification (RQ) units. Error bars represent the standard error of the mean (SEM) and indicate
the calculated minimum (RQMin) and maximum (RQMax) of the mRNA expression levels based
on a RQMin/Max of the 95% confidence level. The expression levels between two samples were
considered statistically different (P value of <0.05) when the error bars did not overlap.
3.11 Confocal immunofluorescence microscopy.

tC3H/He MEFs grown to 50% confluency on 15-mm glass coverslips in 12-well plates were
infected with WNV Eg101 at a MOI of 5. The cells were fixed with 4% paraformaldehyde in
PBS for 10 min at RT and then permeabilized with 0.1% Triton X-100 in PBS for 10 min.
Coverslips were washed with PBS, blocked overnight in 5% heat-inactivated horse serum
(Invitrogen) in PBS, and then incubated with mouse anti-dsRNA antibody (English and
Scientific Consulting Bt, Hungary) diluted 1:500 in the blocking buffer or with rabbit antiSTAT2 antibody (generously provided by Christian Schindler, Columbia University, New York,
NY) diluted 1:200 for 1h at room temperature. The coverslips were washed three times with PBS
and incubated with donkey anti-mouse Alexa Fluor 594 or donkey anti-rabbit Alexa Fluor 488
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secondary antibodies (Invitrogen) diluted 1:400 in blocking buffer containing 0.5 g/ml of
Hoescht 33342 dye (Invitrogen). The coverslips were washed with PBS and mounted on glass
slides with Prolong Gold Antifade reagent (Invitrogen). Cells were visualized with a 40x oilimmersion objective on a LSM 700 laser confocal microscope (Zeiss, Oberkochen, Germany)
using LSM 5 (version 4.2) software (Carl Zeiss Inc.). All of the images compared were obtained
using the same instrument settings.

3.12 Western blotting.

Whole tC3H/He cell extracts were prepared using radioimmunoprecipitation assay buffer [1x
PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS containing Halt Protease and
Phosphatase Inhibitor Single-Use Cocktail (Thermo Scientific). t129 MEF and STAT2-/- MEF
nuclear and cytoplasmic extracts were prepared using Nuclear Extract kit (Active Motif)
according to the manufacturer’s protocol. Following separation by SDS-polyacrylamide gel
electrophoresis (PAGE), the proteins were electrophoretically transferred to a nitrocellulose
membrane. The membrane was blocked with Tris-buffered saline pH 8, containing 5% dry milk
(5% bovine serum albumin was substituted for milk when phosphorylated proteins were
detected) and 0.1% Tween-20 for 1 h at 22°C and then incubated with a polyclonal primary
antibody specific for: STAT1 (Cell Signaling), phospho-STAT1 (Tyr701) (Cell Signaling),
STAT2 (generously provided by Christian Schindler, Columbia University, New York, NY),
phospho-STAT2 (Tyr 690) (Abcam), IRF-9 (Santa Cruz Biotechnology), WNV NS3 (R&D
Systems) or beta-actin (Abcam) overnight at 4°C in the presence of blocking buffer. The blots
were then incubated with anti-rabbit antibody conjugated with horseradish peroxidase (Santa
Cruz Biotechnology) or anti-mouse antibody conjugated with horseradish peroxidase (Cell
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Signaling) for 1 h at 22°C and processed for enhanced chemiluminescence using a Super-Signal
West Pico detection kit (Thermo Scientific) according to the manufacturer's instructions.
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ADDITIONAL DATA

The results of this study showed that ISGs including Oas1a, Oas1b, Irf7 and Irf1 are upregulated
in a type I IFN-independent manner by WNV Eg101 infection. A previous analysis of the
induction of ISGs in pC3H/He MEFs infected with WNV Eg101 showed that one subset of
genes including Oas1a, Oas1b and Irf7 was efficiently upregulated by WNV Eg101 at early
times after infection while the upregulation of a second subset of ISGS including Irf1 was
delayed (Scherbik et al., 2007) suggesting differential regulation of these two subsets of ISGs.
Consistent with this hypothesis, the results of this study confirmed that the two ISG subsets are
regulated by different sets of TFs in WNV Eg101-infected MEFs. The expression of Oas1a,
Oas1b and Irf7 was shown to depend on IRF-9 TF and additional as yet unknown transactivating
factors. Either IRF-3 or IRF-7 enhanced the upregulation of these genes at later times after
infection. However, Irf1 was shown not to be regulated by any of these transcription factors in
WNV-infected cells.
As a means of determining which TFs might be involved in the activation of Irf1 in WNV
Eg101-infected MEFs, the involvement of the mitogen activated protein kinase (MAPK)
pathways that are involved in numerous signaling events were first analyzed. There are three
major MAPK signaling pathways: c-Jun N-terminal kinase (JNK), extracellular signal-regulated
kinase (ERK) and p38 (Chang and Karin, 2001) (Fig. 3.8A). Both the ERK (Scherbik and
Brinton, 2010) and JNK (Scherbik, Courtney and Brinton, unpublished data) pathways are
activated in cells infected with WNV Eg101. The involvement of the JNK and ERK signaling
pathways in the upregulation of ISG mRNA production in WNV Eg101-infected MEFs was
analyzed using pathway specific inhibitors. The JNK II inhibitor (anthra[1,9-cd]pyrazol-6(2H)one, 1,9-pyrazoloanthrone) (Calbiochem) is a specific inhibitor of JNK while U0126 (1,4-
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diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene) (Cell Signaling) is a highly
selective inhibitor of the ERK kinases MEK 1 and MEK 2. Cells that were mock-treated or
infected with WNV Eg101 at a MOI 5 were incubated with the JNK or ERK inhibitor at
concentration of 50µM or with DMSO (vehicle control) for 24h. Prior to collecting total RNA,
replicate mock-treated cells were incubated with 1000 U/ml of IFN beta for 3h. Total RNA was
extracted and the upregulation of Oas1a, Oas1b and Irf1 mRNA was analyzed by real time qRTPCR. No reduction in the expression of Oas1a, Oas1b or Irf1 was observed in cells incubated
with either the ERK or JNK inhibitor compared to cells treated with DMSO (Fig. 3.8B, C and D)
indicating that these pathways are not required for the induction of Oas1a, Oas1b or Irf1 by IFN
beta or WNV Eg101 infection.
Although it was reported that p38 can be activated by dsRNA or encephalomyocarditis virus
(ECMV) infection in a PKR- and RNase L- independent manner (Iordanov et al., 2000), the
activation of the p38 MAPK pathway during WNV Eg101 infection was not previously tested.
The p38 kinase is activated by the MAPK kinases, MKK3, MKK4 and MKK6, through dual
phosphorylation of p38 on Thr180 and Tyr182 (Bellon et al., 1999; Davis, 2000; Chang and
Karin, 2001). To determine whether p38 was activated during WNV Eg101 infection of tC3H/He
cells, Western blotting of cell extracts using antibodies against p38 phosphorylated at Thr180
andTyr182 was done at different times after infection (Fig. 3.9A). A decrease in both total and
phospho-p38 was observed at 8h after WNV Eg101 infection compared to control samples.
However, a robust increase in phospho-p38 was observed in cells infected with WNV Eg101 for
24 or 32 h indicating that p38 was activated at these times after infection. To determine whether
the p38 pathway is involved in the upregulation of Oas1a, Oas1b and Irf1 in WNV Eg101infected MEFs, the mRNA levels of these genes were measured in mock-treated, IFN beta
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Figure 3.8. Analysis of the involvement of the ERK and JNK MAPK pathways in the
upregulation of ISG mRNAs in WNV Eg101-infected MEFs. (A) MAPK cascades. tC3H/He
cells that were mock- or WNV Eg101-infected (MOI of 5) for 24 h were incubated with ERK
inhibitor or JNK inhibitor at a final concentration of 50 µM or with DMSO. Prior to collecting
total RNA, replicate cultures of mock-treated cells was incubated with 1000 U/ml of IFN beta for
3h. (B) Irf1, (C) Oas1a and (D) Oas1b mRNA levels were analyzed by real time qRT-PCR. The
mRNA level of each gene was normalized to the level of GAPDH mRNA in the same sample
and is shown as the fold change over the amount of mRNA in mock samples expressed in
relative quantification units (RQU). Error bars represent the SE (n = 3) and are based on an
RQMin/Max of the 95% confidence level.
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Figure 3.9. Analysis of the activation and involvement of the p38 MAPK pathway in the
upregulation of ISG mRNAs in WNV Eg101-infected MEFs. (A) tC3H/He MEFs were mockor WNV Eg101-infected (MOI of 5) for 24 or 32 h or treated with 1000 U/ml of IFN beta. Cell
lysates were analyzed by Western blotting using antibodies against p38 (Cell Signaling), p38
phosphorylated at Thr 180 and Tyr 182 (Cell Signaling) or beta actin (loading control) (Abcam).
tC3H/He MEFs mock- or WNV Eg101-infected (MOI of 5) were incubated with 20 µM of p38
inhibitor or with DMSO. Prior to collecting total RNA, replicate mock-treated cultures were
incubated with 1000 U/ml of IFN beta for 3h. (B) Irf1, (C) Oas1a and (D) Oas1b mRNA levels
were analyzed by real time qRT-PCR. The mRNA level of each gene was normalized to the level
of GAPDH mRNA in that sample and is shown as the fold change over the amount of mRNA in
mock samples expressed in RQU. Error bars represent the SE (n = 3) and are based on an
RQMin/Max of the 95% confidence level.
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treated and infected cells incubated in the presence of 20 µM of the p38 inhibitor SB202190
(Calbiochem) or DMSO. The expression of Oas1a in cells treated with IFN beta or infected with
WNV Eg101 was not affected by the inhibitor (Fig. 3.9C). However, inhibitor treatment of cells
infected for 24 or 32 h reduced the expression of Irf1 by 70% or more (Fig. 3.9B) indicating that
the p38 pathway is important for the upregulation of Irf1 in WNV Eg101-infected MEFs. In
contrast, no reduction in Irf1 mRNA levels was observed in IFN-treated cells in the presence of
the inhibitor. However, the expression of Oas1b was decreased by about 30% in cells treated
with IFN and by about 50% in cells infected for 32 h (Fig. 3.9D) suggesting that p38 might play
a partial role in the upregulation of Oas1b by IFN and during WNV Eg101 infection.
A TFBS analysis of the Irf1 promoter sequence predicted the presence of NF-kappa B binding
sites (Harada et al., 1994; Pine et al., 1994) and consistent with this prediction a previous study
showed that Irf1 gene expression was induced by this TF (Pahl, 1999). Also, NF-kappa B was
shown to be activated in WNV Eg101-infected MEFs (Scherbik, Pulit-Penaloza and Brinton,
unpublished data). The involvement of NF-kappa B components in upregulating Irf1 in infected
cells

was

tested

using

the

NF-kappa

B

activation

inhibitor

6-amino-4-(4-

phenoxyphenylethylamino)quinazoline. tC3H/He MEFs were mock-treated, infected with WNV
Eg101 at a MOI of 5 for 24 h or treated with 1000 U/ml of IFN beta for 3 h and then incubated
with media containing the NF-kappa B inhibitor at concentrations of 5, 30 or 60 nM or with
DMSO for 24 h prior to harvesting RNA from cells. Real time qRT- PCR was done to determine
the levels of Oas1a, Oas1b and Irf1 mRNA in each sample. The results showed that inhibition of
NF-kappa B did not affect the upregulation of Oas1a (Fig. 3.10A) suggesting that the
upregulation of Oas1a in MEFs infected with WNV Eg101 is not mediated by NF-kappa B.
However, a dose dependent decrease in the expression of Oas1b was observed in inhibitor
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Figure 3.10. Analysis of the involvement of NF-kappa B in the upregulation of ISG mRNAs
in WNV Eg101-infected MEFs. tC3H/He MEFs mock or WNV Eg101infected (MOI of 5) for
24 or 32 h were incubated with NF-kappa B inhibitor at a final concentration of 5, 30 or 60 nM
or with DMSO. Prior to collecting total RNA, replicate mock-treated cultures were incubated
with 1000 U/ml of IFN beta for 3h. (A) Irf1, (B) Oas1a and (C) Oas1b mRNA levels were
analyzed by real time qRT-PCR. The mRNA level of each gene was normalized to the level of
GAPDH mRNA in the same sample and is shown as the fold change over the amount of mRNA
in mock samples expressed in RQU. Error bars represent the SE (n = 3) and are based on an
RQMin/Max of the 95% confidence level.
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treated cells also treated with IFN as well as in infected cells (Fig. 3.10B) suggesting that NFkappa B plays a partial role in the upregulation of this gene by IFN beta and WNV Eg101
infection. Oas1b contains an NF-kappa B site located just downstream of the ISRE, while Oas1a
does not. Although this site was shown not to be involved in the activation of the Oas1b
promoter by IFN beta, it could play a role in the upregulation of Oas1b in an IFN-independent
manner in WNV Eg101-infected MEFs. Analysis of the Oas1b promoter by GENOMATIX
predicted three additional NF-kappa B binding sites upstream of the ISRE which might also play
a role in regulating Oas1b expression induced by IFN beta and/or WNV Eg101 infection. In
contrast, the NF-kappa B inhibitor did not affect Irf1 expression in cells treated with IFN beta
but reduced the expression of Irf1 in WNV Eg101-infected cells to the levels observed in mock
at both 30 and 60 nM concentrations (Fig. 3.10C).
The mammalian NF-kappa B family consists of RelA (p65), NF-kappa B1 (p50/p105), NF-kappa
B2 (p52/p100), c-Rel, RelB. RelA, RelB and c-Rel. Each subunit has a carboxy-terminal
activation domain and is involved in transcriptional activation of promoters that contain NFkappa B sites. p50 and p52 lack a transactivation domain but can still bind NF-kappa B sites and
repress gene expression. Each member of the NF-kappa B family can form heterodimers and/or
homodimers with one another. The most common form of NF-Kappa B is the p65/p50
heterodimer (Li and Verma, 2002; Pomerantz and Baltimore, 2002). To further investigate the
involvement of NF-kappa B in the upregulation of Irf1 in WNV Eg101-infected MEFs, Irf1
mRNA levels as well as those of Oas1a and Oas1b mRNAs were analyzed in cells with either the
p65 or p50 subunit of NF-kappa B knocked out. As expected based on the results with the NFkappa B inhibitor, the upregulation of Oas1a by WNV Eg101 infection was not affected in either
cell line (Fig. 3.11B and E). Oas1b mRNA levels were reduced in p65-/- MEFs treated with IFN
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Figure 3.11. Analysis of the involvement of the p65 and p50 NF-kappa B subunits in the
upregulation of ISG mRNAs in WNV Eg101-infected MEFs. (A-C) p65-/- MEFs or p65-/MEFs stably transfected with a p65 expression vector (control), (D-E) C57BL/6 (wild type)
MEFs or p50-/- MEFs. Cells were mock- or WNV Eg101-infected (MOI of 5) for the indicated
times or treated with 1000 U/ml of IFN beta. Total RNA was collected and the Oas1a, Oas1b and
Irf1 mRNA levels were analyzed by real time qRT-PCR. The mRNA level of each gene was
normalized to the level of GAPDH mRNA in the same sample and is shown as the fold change
over the amount of mRNA in mock samples expressed in RQU. Error bars represent the SE (n =
3) and are based on an RQMin/Max of the 95% confidence level
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beta (Fig. 3.11C). However, the expression of Oas1b and Irf1 in WNV Eg101-infected p65-/MEFs was reduced but only at late times after infection (32 h) with a maximum reduction of
about a three-fold (Fig. 3.11A and C). These data suggest a partial role for p65 in regulating the
expression of Oas1b and Irf1 in infected cells. A slight but not a significant reduction in the Irf1
mRNA at 32 h was observed in WNV Eg101-infected p50-/- MEFs (Fig. 3.11E) suggesting that
the p50 subunit of NF-kappa B is not required for the upregulation of Irf1. In contrast, a
significant increase in Oas1b mRNA levels at 8, 16 and 24 h after infection was observed in
WNV Eg101-infected p50-/- MEFs (Fig 3.11 F) suggesting that p50 subunit of NF-kappa B may
play a role in downregulating Oas1b in infected cells. The p50/p50 homodimer is known to be a
transcriptional repressor (Li and Verma, 2002; Pomerantz and Baltimore, 2002).
The data indicate that both the p38 and NF-kappa B pathways are involved in Irf-1 and Oas1b
gene regulation in WNV Eg101-infected MEFs. It is possible that NF-kappa B may be activated
by p38 in infected cells since the involvement of p38 in the activation of NF-kappa B was
previously reported (Maulik et al., 1998; Vanden Berghe et al., 1998; Liang and Gardner, 1999;
Saha et al., 2007).
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CHAPTER 4

4

AIM 3. Translational suppression of IRF-1 expression in WNV Eg101-infected cells.

INTRODUCTION
IRF-1 is a transcription factor that induces the expression of various antiviral genes including
IFN-alpha and IFN-beta, MHC class I and some ISGs (Miyamoto et al., 1988; Taniguchi et al.,
2001; Schoggins et al., 2011). Recent studies demonstrated the importance of IRF-1 in inhibiting
the replication of many viruses including WNV (Jiang et al., 2010; Schoggins et al., 2011). In
addition, studies using IRF-1 knockout mice showed that IRF-1 mediates a broad spectrum of
antiviral processes in response to IFN gamma. Mice lacking IRF-1 showed defects in maturation
and development of various types of immune cells (Paun and Pitha, 2007).
In contrast to other ISGs such as Irf7, Oas1a and Oas1b which are induced at 12 h after WNV
Eg101 infection of tC3H/He MEFs, the induction of Irf1 is delayed until 24 h after infection
(Scherbik et al., 2007). Although the levels of Irf1 mRNA in MEFs infected with WNV Eg101
for 24 h and MEFs treated with IFN beta for 3 h are similar, only a small increase in IRF-1
protein levels is observed in infected cells in contrast to the high IRF-1 levels in type I IFNtreated MEFs suggesting translational repression of IRF-1 in WNV Eg101-infected cells
(Scherbik et al., 2007).
Protein expression can be regulated post-transcriptionally at the level of mRNA synthesis,
mRNA turnover, translation or protein turnover. Since induction of IFN is the initial host cell
response against viral infection, many viruses have developed strategies to circumvent either the
upregulation of IFN genes or the induction of IFN signaling in order to block the upregulation of
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the genes encoding antiviral proteins (Randall and Goodbourn, 2008). Induction of increased
cellular mRNA decay was previously reported to be mediated by Kaposi’s sarcoma virus, EBV
and herpes simplex virus (HSV) infections (Glaunsinger and Ganem, 2004; Feng et al., 2005;
Lee and Glaunsinger, 2009; Clyde and Glaunsinger, 2010). Adenovirus, influenza virus and VSV
infections have been shown to interfere with mRNA trafficking by blocking the export of cellular
mRNAs from the nucleus (Faria et al., 2005; Satterly et al., 2007; Yatherajam et al., 2011). Cell
protein levels are most commonly blocked by viruses at the level of translation. A variety of
viruses have been reported to inhibit global translation through targeting either initiation factors,
including 4EBP1, eIF4E, eIF4G, eIF4A, eIF5B, eIF3 and eIF2 or elongation factors, including
eEF1A and eEF1B, or release factor eRF1, or PABP or ribosomes (reviewed in (Walsh and
Mohr, 2011)). However, none of these mechanisms are limited to only a subset of genes.
Transcript specific translation regulation can be achieved by the binding of cell proteins to cisacting elements, such as AU rich elements (ARE), in the 3'UTRs of target mRNAs (Zhang et al.,
2002; Abaza and Gebauer, 2008) or by the binding of specific miRNAs to target mRNAs
(Eulalio et al., 2008; Hutvagner and Simard, 2008). The binding of proteins to AREs can lead to
destabilization or stabilization of a mRNA or cause translational suppression (silencing) (Zhang
et al., 2002). miRNAs can also specifically regulate the stability or translation of target mRNAs.
Some viruses encode miRNAs while others induce or repress the expression of particular host
miRNAs. For example, expression of EBV latent membrane protein 1 was shown to induce the
expression of cellular miR-146a that plays a role in the antiviral response (Motsch et al., 2007;
Cameron et al., 2008). An enterovirus infection was reported to induce host miR-141 miRNA
which specifically targets eIF4E mRNA leading to inhibition of cap-dependent initiation of
protein translation (Ho et al., 2011). HIV infection was shown to repress a polycistroninc cluster
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of cell miRNAs and this allows more efficient replication (Triboulet et al., 2007). Herpesviruses
encoded miRNAs were shown to target viral lytic genes as well as host genes involved in the
induction of the innate antiviral immune response and apoptosis (Skalsky and Cullen, 2010).
RESULTS
4.1

Analysis of the expression of IRF-1 in WNV Eg101-infected tC3H/He MEFs.

A previous analysis of ISG expression in primary C3H/He MEFs showed that both Irf1 mRNA
and protein levels were upregulated in cells treated with IFN beta for 3 h. However, although Irf1
transcript levels were upregulated to similar levels at 24 h after infection with WNV Eg101 and 3
h after treatment with IFN beta, IRF-1 protein levels increased only slightly over those in control
cells (Scherbik et al., 2007). To determine whether IRF-1 translational suppression also occurs in
transformed C3H/He (tC3H/He) MEFs, the cells were mock- or WNV Eg101-infected (MOI of
5) or IFN beta-treated and total RNA and cellular lystates were collected and analyzed by real
time qRT-PCR or Western blotting. Similar to the results of the previous study (Scherbik et al.,
2007), mRNA levels of Irf1 were significantly upregulated (Fig. 4.1A) but only a small increase
in IRF-1 protein levels was observed in the WNV Eg101-infected transformed MEFs (Fig. 4.1B).
In contrast, STAT1 protein levels, were significantly upregulated at 24 and 32 h after WNV
Eg101 infection and at 3 h after IFN treatment. As an additional means of confirming the
translational suppression of IRF-1 in WNV Eg101-infected cells, tC3H/He cells were infected
with WNV Eg101 at a MOI of 5 and 3 h before cell harvest, cells were treated with 1000 U/ml of
IFN beta or left untreated. As expected mRNA levels in WNV Eg101-infected increased at 19
and 27 h after infection (Fig. 4.1C). Similar high levels of Irf1 mRNA were observed in samples
from mock-treated or infected cells treated with IFN beta prior to harvesting (Fig. 4.1C).
Increased IRF-1 protein levels were observed in mock-treated and 5 h WNV infected cells
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Figure 4.1. Expression of IRF-1 in WNV Eg101-infected tC3H/He MEFs. tC3H/He MEFs
were mock-infected or infected with WNV Eg101 at a MOI of 5 for the indicated times or
treated with 1000 U/ml of murine IFN beta for 3 h. (A) Total RNA from tC3H/He MEFs was
extracted and Irf1 mRNA levels were measured by real-time qRT-PCR. (B) tC3H/He cell lysates
were analyzed by Western blotting using antibodies specific for the indicated proteins. (C, D)
tC3H/He MEFs were mock-infected or infected with WNV Eg101 at a MOI of 5 for the
indicated times. Three h before collecting total RNA or cell lysates, the cells were either treated
with 1000 U/ml of murine IFN beta for 3 h or left untreated. (C) Irf1 mRNA levels were
measured by real-time qRT-PCR. (D) IRF-1 protein expression in cell lysates was analyzed by
Western blotting using specific antibodies. In each real time qRT-PCR experiment, the mRNA
level of each gene was normalized to the level of GAPDH mRNA in the same sample and shown
as the fold change over the amount of mRNA in mock samples expressed in relative
quantification units (RQU). Error bars represent the SE (n = 3) and are based on an RQMin/Max of
the 95% confidence level. Actin was used as a loading control in each Western blot experiment.
The blots shown are representative of the results obtained from at least two independent
experiments.
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Figure 4.2. The effect of the proteasomal inhibitor MG132 or IRF-1 protein levels in
tC3H/He MEFs. Fig. 4.2. tC3H/He MEFs were mock-infected, infected with WNV Eg101 at a
MOI of 5 for the indicated times or treated with 1000 U/ml of murine IFN beta. Six hours before
collecting cell lysates, the cells were treated with MG132 (25 M) or DMSO. (A) IRF-1 protein
levels in cell lysates were analyzed by Western blotting. Actin was used as a loading control. (B)
Results obtained from three independent Western blot experiments were quantified by
densitometry using ImageJ software. The average results were summarized graphically as the
ratio of band intensity DMSO/MG132. Error bars indicate SDM (n=3). (C) Culture fluid from
samples harvested at the indicated times after infection were titered for infectivity by plaque
assay. Each data point is the average of duplicate titrations from at least two experiments. Error
bars indicate SDM (n=3).
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treated with IFN but the protein levels in the IFN-treated infected cells decreased with increasing
time after infection (Fig. 4.1D).
4.2

The effect of a proteasomal inhibitor on IRF-1 protein levels in MEFs infected with
WNV Eg101.

Since decreased protein levels could be due to increased proteasomal degradation, the extent of
protein turnover was analyzed using the proteasome inhibitor MG132. tC3H/He MEFs were
mock-infected, infected with WNV Eg101 at a MOI of 5 for the indicated times or treated with
1000 U/ml of murine IFN beta for 3 h. Six hours before collecting cell lysates, the cells were
treated with MG132 (Calbiochem) (25 M) or DMSO (vehicle control). Protein expression in
cell lysates was analyzed by Western blotting using antibodies specific for IRF-1 (Fig. 4.2A and
B). IRF-1 has a 30 m half-life (Watanabe et al., 1991) and in the presence of the proteasomal
inhibitor, high levels of IRF-1 accumulated in cells treated with IFN consistent with increased
synthesis of IRF-1 in these cells. In contrast, the levels of IRF-1 in mock-treated cells and
infected cells treated with the inhibitor were similar suggesting that only low basal IRF-1 levels
are produced and no enhancement of IRF-1 translation occurs in infected cells. These results
suggest that the low IRF-1 protein levels in infected cells are not due to enhanced proteasomal
degradation of IRF-1 but to a lack of increased IRF-1 translation. MG132 treatment had no effect
on viral replication (Fig. 4.2C).
4.3

WNV infection does not lead to production of alternatively spliced variants of Irf1
mRNAs.

One mechanism of altering gene expression is by inducing alternative splicing of a mRNA
species. Exon skipping can result in the loss of the initiation codon preventing translation
initiation (Harada et al., 1994; Maratheftis et al., 2006). To test whether the IRF-1 translational
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Figure 4.3. Comparison of the sizes of Irf1 mRNA transcripts in mock- or WNV Eg101infected or IFN beta-treated MEFs. tC3H/He cells were mock-infected, infected with WNV
Eg101 (MOI of 5) for 12 or 24 h or treated with 1000 U/ml IFN beta for 3 h. Total RNA was
extracted and used for RT-PCR with primers specific for Irf1. Amplified cDNA was resolved on
a 1% agarose gel.
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suppression is due to production of alternatively spliced isoforms of Irf1 in WNV Eg101infected cells, total RNA was isolated from cells that were mock-treated, infected with WNV
Eg101 at MOI 5 or treated with 1000 U/ml of IFN beta for 3 h and analyzed by RT PCR. Only a
single size Irf1 transcript band was detected in cells from the three conditions (Fig. 4.3)
indicating that the IRF1 translational suppression is not due to alternative splicing of Irf1 mRNA.
4.4

The effect of the Irf1 3'UTR on luciferase reporter expression in WNV infected cells.

To determine whether the 3'UTR of Irf1 mRNAs contains elements required for translation
suppression in WNV infected cells, a firefly luciferase reporter gene with the Irf1 3 'UTR under
the control of eIF1 alpha promoter was cloned into the pGL3 vector (Promega) (Fig. 4.4A). The
expression vector containing Irf1 3'UTR or the control vector (luciferase reporter gene with the
firefly luciferase 3'UTR under the control of eIF1 alpha promoter) were co-transfected with the
pGL4.74 Renilla luciferase reporter construct into tC3H/He MEFs. At 24 h after transfection, the
cells were either mock- or WNV Eg101-infected at a MOI of 5 for 24 h. Firefly luciferase
activity produced by the reporter vector containing the Irf1 3 'UTR was normalized to the
luciferase activity produced by a control luciferase reporter vector. The eIF1 alpha promoter
provides constitutive expression of the firefly luciferase gene. Lower luciferase activity was
expected in cells that were infected compared to mock-treated cells. However, no significant
difference in the luciferase activity was observed in infected and uninfected cells suggesting that
the presence of Irf1 3'UTR downstream of the firefly luciferase gene does not negatively regulate
the expression of firefly luciferase in infected cells (Fig.4.4B).
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Figure 4.4. Analysis of the effect of the Irf1 3’UTR on firefly luciferase reporter gene
expression. (A) The Irf1 3'UTR DNA fragment was cloned immediately downstream of the
firefly luciferase reporter gene. (B) The Luc-Irf1 3'UTR or a control Luc vector were cotransfected with the pGL4.74 Renilla luciferase reporter construct into tC3H/He MEFs. Twenty
four hours after transfection, cell lysates were collected and luciferase activity was measured
using a luminometer. Firefly luciferase activity measured in triplicate was normalized to Renilla
luciferase activity and the activity of the firefly luciferase control vector. The error bars represent
SDM (n=3).
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Figure 4.5. Effect of dicer knock-down on the protein levels of IRF-1 in cells infected with
WNV Eg101. tC3H/He cells were transfected with dicer siRNA (20nM) or scrambled control
siRNA (20nM) for 24 h and then infected with WNV Eg101 (MOI of 5) or treated with 1000
U/ml of IFN beta for 3 h. Cell lysates were collected and Western blotting was done using
antibodies to the the indicated proteins. Actin was used as a loading control. The results shown
are representative of two independent experiments.
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4.5

Analysis of the effect of dicer knock-down on IRF-1 protein levels in WNV Eg101infected.

Transcription specific suppression of translation can be mediated by the binding of miRNAs to
the 3'UTRs of target mRNAs (Eulalio et al., 2008). As one means of investigating whether the
suppression of IRF-1 translation during WNV infection is mediated by miRNAs, tC3H/He MEFs
were transfected with nonspecific or dicer-specific siRNAs and 24 h later, the cells were infected
with WNV Eg101 at a MOI of 5. In cells transfected with scrambled siRNA, dicer protein levels
were almost undetectable in mock-treated cells (Fig. 4.5). An increase in dicer levels was
observed in cells infected for 8 h. Although the levels remained above those in mock-infected
cells throughout the infection, they decreased by 24 h after infection. In cells transfected with
dicer specific siRNAs, efficient knock down of dicer was observed in infected cells. Analysis of
IRF-1 protein levels in cells transfected with nonspecific siRNAs showed efficient IRF-1 protein
production upon IFN stimulation and less efficient IRF-1 production in WNV infected cells. A
small increase in IRF-1 protein levels in infected cells transfected with specific siRNAs was
observed suggesting that miRNAs might be involved in regulating IRF-1 translational
suppression. Interestingly, higher IRF-1 protein levels were observed in mock-infected cells that
were transfected with dicer-specific siRNAs than in mock-treated cells that were transfected with
nonspecific siRNAs. This result suggests that basal expression of IRF-1 in unstimulated cells
may be regulated by miRNAs.

DISCUSSION
Viruses depend entirely on the host translational machinery for synthesis of the viral proteins
required for viral replication and the assembly of viral particles. Many viruses have evolved
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mechanisms to control host protein synthesis in order to suppress the production of antiviral
proteins. Since IRF-1 has demonstrated antiviral activity against WNV (Schoggins et al., 2011),
it would be beneficial for the virus to suppress IRF-1 production. In this study analysis of the
production of IRF-1 protein in transformed C3H/He cells confirmed the previously published
observation that IRF-1 levels in WNV Eg101-infected primary C3H/He cells remained similar to
those in mock-treated cells even though the Irf1 mRNA levels increased significantly in the
infected cells. Since IRF-1 has a short half-life (about 30 m) (Watanabe et al., 1991), the levels
of this protein would be expected to increase in the presence of the proteasomal inhibitor
MG132. The levels of IRF-1 in cells treated with IFN beta and MG132 increased indicating that
IFN beta induced increased translation of IRF-1. However, the levels of IRF-1 in mock-treated or
WNV Eg101-infected cells increased only slightly after treatment with the inhibitor indicating
that IRF-1 is constantly translated at a low basal level in control cells and that this does not
change with infection.

Transcript specific suppression of translation can occur due to the binding of proteins to cisacting elements in the 3'UTRs of target mRNAs (Kuersten and Goodwin, 2003; Mazumder et al.,
2003; Abaza and Gebauer, 2008). In many instances, translational control is mediated by AREs
located in the 3'UTR of mRNAs (Chen and Shyu, 1995). Analysis of the Irf1 3'UTR sequence
with the ARE database program showed the presence of AREs and suggested the possibility that
3'UTR mediated regulation may be occurring in WNV Eg101-infected cells. Transcript specific
translational inhibition can also be mediated by binding of miRNAs to regions of the 3'UTR of a
target mRNA (Lytle et al., 2007). However, the Irf1 3'UTR did not suppress the translation of a
reporter gene. The insertion of the Irf1 3'UTR downstream of a heterologous gene could have
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altered mRNA folding which prevented protein binding to Irf1 3'UTR. Alternatively, the
endogenous factors (proteins and/or miRNAs) may not be expressed at sufficient levels to
suppress the translation of the overexpressed 3'UTRs. Additional experiments need to be done
before the involvement of the Irf1 3'UTR in translational suppression can be ruled out.

Analysis of ISG mRNAs by real time qRT-PCR showed that the basal Irf1 mRNA levels in
untreated cells are more than 100 fold higher than the mRNA levels of other ISGs including
Oas1a, Oas1b and Irf7 (data not shown). The observation that relatively high basal levels of Irf1
mRNA are induced in untreated cells but protein levels are very low suggests the presence of a
mechanism that tightly controls the amount of IRF-1 protein produced at basal levels. In contrast,
when the cells are stimulated with type I IFN, Irf1 mRNA levels increase by tenfold or more and
the translational suppression mechanism is overcome resulting in high IRF-1 protein levels.
However, in the case of a WNV Eg101 infection, a similar increase in Irf1 mRNA levels does
not result in relief of the translational suppression and low IRF-1 protein levels are observed. It
appears that the WNV infection induces an increased suppression of IRF-1 translation to
accommodate the increased Irf1 mRNA levels. One possibility is that Irf1 mRNA may be
sequestered in P-bodies. It was previously shown that mRNAs with miRNAs bound to them are
sequestered in P-bodies (Parker and Sheth, 2007). The preliminary results suggest that IRF-1
protein levels might be regulated by miRNAs. The observations that Irf1 mRNA levels in
untreated cells are higher than those of other ISGs and that knock-down of dicer resulted in an
increase in IRF-1 protein levels in mock-treated cells suggested that miRNAs might be involved
in maintaining low basal levels of IRF-1. Since the use of siRNAs does not result in a complete
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knock-down of expression, the experiments need to be repeated in cells that have dicer depleted
through homologous recombination (Tan et al., 2009).
Although, it was previously reported that translation initiation can be also blocked through the
binding of RNA binding proteins to cis-elements in the 5'UTR of a target message (Garfinkel
and Katze, 1993; Damgaard and Lykke-Andersen, 2011), the required sites for this type of
regulation were not predicted in the 5'UTR of Irf1. It is also unlikely that the translational
suppression is mediated by miRNAs binding to the Irf1 5'UTR or ORF. Binding of miRNAs to
these sites were shown to produce less effective silencing of translation (Lytle et al., 2007).
MATERIALS AND METHODS
4.6

Cells and viruses.

SV40-transformed tC3H/He (tC3H/He) MEFs were grown in minimal essential medium (MEM)
supplemented with 5% fetal bovine serum (FCS) and 10 µg/ml gentamicin. The cells were grown
at 37°C in a 5% CO2 atmosphere.
To prepare a lineage I WNV strain Eg101 stock, BHK cells were infected at a MOI of 0.1 and
culture fluid was collected 32 h after infection. The virus was titered by plaque assay. The titer of
the stock virus was ~ 1 x 108 PFU/ml.
4.7

Cloning of the Irf1 3'UTR.

The Irf1 3'UTR was amplified by PCR using primers designed based on the GenBank sequence
NM_008390.2.

The

sequence

of

the

Irf1

forward

primer

was

5'

ATCTAGATTTGGGTCTCTGACCCGTTCTTGCCCTCC 3', and that of the Irf1 reverse primer
was 5' ATCTAGAGTAAACAACTTAAATTTTTATAAAAAGAC 3'. Each PCR reaction
consisted of 100 ng of tC3H/He MEF genomic DNA, 200 M dNTP mix, 0.2 M of the specific
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forward and reverse primers, 1X BD Advantage 2 Polymerase Mix and 1X BD Advantage 2
PCR Buffer (BD Biosciences Clontech). The amplified Irf1 3 'UTR was cloned into the Topo-XL
vector and the sequence was verified by sequencing. The DNA fragment was then subcloned into
a modified pGL3 basic firefly luciferase reporter vector (Promega) containing the eIF1 alpha
promoter using XbaI cloning sites to construct the Luc-Irf1 3’UTR construct.
4.8

Luciferase assay.

Luc-Irf1 3'UTR firefly luciferase reporter plasmid DNA or control firefly luciferase reporter
plasmid (1µg) and pGL4.74 Renilla luciferase reporter construct DNA (20 ng) (Promega) were
added to a solution containing 3 l of FuGENE 6 (Roche Applied Science) and 97 l of serum
free media. Cells at about 70% confluency were transfected and then incubated at 37C for 24 h.
Next, the cells were infected with WNV Eg101 at a MOI of 5 for 24 h and then harvested
according to the Dual Luciferase Reporter Assay System (Promega) protocol. Firefly and Renilla
luciferase activities were separately measured using a luminometer (LMax II384, Molecular
Devices). The firefly luciferase activity obtained for each sample was divided by the Renilla
luciferase activity and the results were then normalized to the results obtained with a control
construct without an Irf1 3'UTR.
4.9

Quantification of mRNA levels.

Real-time qRT-PCR analyses of mouse Irf1 gene expression were performed using an Applied
Biosystems 7500 Sequence Detection System with Applied Biosystems Assays-on-Demand
primer and fluorogenic TaqMan FAM/MGB probe mix Mn01288580_m1 Ifr1 and a One-Step
RT-PCR Master Mix Reagent Kit (Applied Biosystems) according to the manufacturers’
protocol. The reaction was set up as followes: reverse transcription at 48°C for 30 m, activation
at 95°C for 10 m, denaturation at 95°C for 15 s, and annealing/extension at 60°C for 1 m (cycle
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repeated 40 times). Each value was normalized to that of GAPDH detected using TaqMan
primers and probe (Applied Biosystems). The values are shown as the relative fold change
compared to the mock-infected calibrator sample in RQUs..
4.10 RT-PCR analysis of Irf1 mRNA splice variants.
Analysis of Irf1 splice variants was done using the SuperScript III One-Step RT-PCR system
with a Platinum Ta2 DNA polymerase kit (Invitrogen). Total RNA was extracted from tC3H/He
MEFs that were mock- or WNV Eg101-infected (MOI of 5) for 12 or 24 h or treated with 1000
U/ml of murine IFN beta. Each reaction was set up according to the manufacturer’s protocol and
contained 0.5 g of RNA per 50 l of reaction volume. The Irf1 forward primer: 5'
AATCTTTCGCTTCGTGCGCGCATCGCG

3'

and

reverse

primer:

5'

TGATGGAGTCCATATTCTTCATCTCCG 3' were complementary to the terminal sequences
of the IRF1 mRNA and were designed based on the GenBank sequence NM_008390. These
primers amplified the entire mRNA. The PCR products were resolved on a 1% agarose gel.
4.11 Western blotting.

tC3H/He cell monolayers were washed with ice-cold PBS and then scraped into
radioimmunoprecipitation assay buffer [1x PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate,
and 0.1% SDS containing Halt Protease and Phosphatase Inhibitor Single-Use Cocktail (100X)
(Thermo Scientific)]. The proteins were separated by 7.5% or 10% SDS-polyacrylamide gel
electrophoresis (PAGE) and then electrophoretically transferred to a nitrocellulose membrane.
The membrane was blocked with 1x Tris-buffered saline pH 8 containing 5% dry milk and 0.1%
Tween-20 for 1 h at 22°C and then incubated with a rabbit polyclonal primary antibody specific
for IRF-1 or dicer (Santa Cruz Biotechnology) or beta-actin (Abcam) overnight at 4°C in the
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presence of blocking buffer. The blots were then incubated with anti-rabbit secondary antibody
conjugated with horseradish peroxidase (Santa Cruz Biotechnology) or anti-mouse secondary
antibody conjugated with horseradish peroxidase (Cell Signaling) for 1 h at 22°C. The proteins
were detected using a Super-Signal West Pico detection kit (Thermo Scientific) according to the
manufacturer's instructions.

4.12 Dicer knock-down using RNAi.
tC3H/He cells at about 70% confluency were transfected with dicer siRNA (20 nM) or
scrambled siRNA (20 nM) (Santa Cruz Biotechnology) using HiPerFect transfection reagent
(Qiagen) according to the manufacturer’s protocol. Twenty four hours after transfection, the cells
were mock- or, WNV Eg101-infected (MOI of 5) for the indicated times or treated with 1000
U/ml of IFN beta for 3 h. Cell lysates were collected for Western blot analysis.
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CHAPTER 5
5

CONCLUSIONS AND FUTURE DIRECTIONS

The majority of WNV infections in humans are asymptomatic. However, in about 1 in 150
infected humans, the infection can induce severe disease (Petersen et al., 2003). Since no
antiviral therapies or vaccines have been developed so far to treat or prevent infections it is
important to gain a better understanding of WNV-host interactions to facilitate future
development of effective treatments. In this study, we analyzed the the strategies utilized by the
host cell to counteract virus-mediated blockage of the the type 1 IFN signaling pathway though
upregulation of ISGs via alternative mechanisms as well as strategies used by WNV Eg101 to
block the expression of an antiviral protein.
5.1

Type I IFN mediated induction of a subset of ISGs in a STAT1 independent manner.

Although ISGs are classically induced by type I IFN through the STAT1/STAT2/IRF-9 trimetric
complex (Pestka et al., 2004), the results of this and other studies suggest that alternative TF
complexes can also activate the expression of some ISGs in IFN-treated cells (Ousman et al.,
2005; Sarkis et al., 2006; George et al., 2008). The observation that the antiviral ISG Oas1b can
be induced by IFN in a STAT1-independent manner indicates that alternative regulatory
complexes can be utilized by the cell to mount an antiviral immune response. The importance of
a STAT2-dependent but STAT-1-independent response to viral infection was previously reported
(Hahm et al., 2005; Perry et al., 2011). However, the components of the complex in the STAT1independent activation of gene expression by IFN is currently not known. IRF-9 was previously
shown to be unable to activate gene expression by binding to the ISRE alone while either an
IRF-9/STAT2 fusion protein or an IRF-9/STAT2 protein complex efficiently activated ISRE-
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driven transcription (Kraus et al., 2003; Lou et al., 2009). However, it is currently not known
whether additional factors are also involved in the STAT1-independent upregulation of ISGs by
type I IFN. To determine whether the STAT2/IRF-9 complex interacts with additional proteins to
induce STAT1 independent transcription, immunoprecipitation experiments in STAT1-/- MEFs
treated with IFN beta could be done. Proteins immunoprecipitated with STAT2 antibody could
be identified by mass spectrometry. It is expected that IRF-9 would be immunoprecipitated with
STAT2 in cells treated with type I IFN. If IRF-9 is the only protein immunoprecipitated with
STAT2 from WNV infected cells, this would suggest that the STAT2/IRF-9 complex is
sufficient for the induction of STAT1-independent upregulation of some ISGs by type I IFN. If
additional factors are identified, it would be interesting to determine the exact DNA motifs
required for the binding of the alternative complex. This could be achieved by EMSA using
nuclear extracts from STAT1-/- MEFs and DNA probes consisting of labeled wild type or
mutated promoter fragments.
5.2

WNV Eg101 mediated blockage of STAT1 and STAT2 translocation to the nucleus of
infected MEFs.

Since the IFN pathway plays a critical role in the induction of innate immune response to
infection it is an attractive target of many viruses. The results of this and other studies showed
that flaviviruses have evolved several mechanisms to effectively block the type I IFN signaling
pathway (Munoz-Jordan et al., 2003; Lin et al., 2004; Best et al., 2005; Guo et al., 2005; Ho et
al., 2005; Jones et al., 2005; Liu et al., 2005; Munoz-Jordan et al., 2005; Keller et al., 2006;
Mackenzie et al., 2007; Mazzon et al., 2009; Laurent-Rolle et al., 2010). The results of this study
showed that the infection of MEFs with lineage 1 WNV strains Eg101 and NY99 induces
phosphorylation of STAT1 and STAT2 but blocks the translocation of these TFs to the nucleus.
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In contrast, lineage I WNV strain TX02 infection of human cells (Keller et al., 2006) and WNV
Eg101 and NY99 infection of human or monkey cells (Scherbik, Pulit-Penaloza and Brinton,
unpublished data) were shown to block the phosphorylation of STAT1 and STAT2. These results
indicate that nuclear translocation of STAT1 and STAT2 in primate cells infected by WNV is
blocked by suppression of STAT phosphorylation required for nuclear translocation while in
murine cells, the blockage occurs at the level of transport of phosphorylated STAT proteins to
the nucleus. Since the murine model is commonly used to study WNV-host interaction, it is
important to understand the differences in the response to viral infection between murine and
human cells. Species specific mechanisms of suppression of STAT signaling have been
previously reported for dengue virus. The dengue virus NS5 protein was shown to bind and
target for degradation human but not murine STAT2 (Ashour et al., 2010). Mice are not a natural
host for dengue virus infections.
The mechanism by which WNV Eg101 blocks STAT1 and STAT 2 translocation to the nucleus
in MEFs is currently not known. One possibility is that the blockage might be due to interference
with the ISGF3 complex-importin interaction. ISGF3 binds importin alpha 5 (also known an
karyopherin alpha 1) which recruits importin beta 1 (karyopherin beta 1). This allows the
passage of the ISGF3 complex through the nuclear pore (McBride et al., 2002; Reich, 2007).
Suppression of STAT1 translocation to the nucleus though blockage of the interaction with
importins was previously reported for Ebola (Reid et al., 2006) and SARS (Frieman et al., 2007)
viruses. Immunoprecipitation experiments could be done to pull down STAT1 or STAT2
proteins and assay for the binding of importin alpha 5. It is expected that this interaction would
be observed in cells treated with IFN beta but not in cells infected with WNV Eg101.
Alternatively, pull down experiments could be done to determine whether STAT1, STAT2 and
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IRF-9 interact to form the trimetric ISGF3 complex in WNV Eg101-infected MEFs. It is possible
that the lack of nuclear translocation is due to inhibition of the assembly of the ISGF3 complex
in infected cells.. If this is the case, STAT1, STAT2 and IRF-9 would immunoprecipitate in
samples from cells treated with IFN beta but not in samples from WNV Eg101-infected cells.
5.3

IFN-independent upregulation of ISGs in MEFs infected with WNV Eg101.

Despite the fact that neither phospho-STAT1 nor phopsho-STAT2 could translocate to the
nucleus in MEFs infected with WNV Eg101, efficient induction of ISGs was observed (Scherbik
et al., 2007) suggesting that the host cell can utilize alternative mechanism(s) to activate ISG
expression. IFN-independent upregulation of some ISGs such as ISG15 and ISG54 can be
mediated by the activation of IRF-3 (Nakaya et al., 2001; Grandvaux et al., 2002; Andersen et
al., 2008). However it is still not clear how IRF-3 independent ISGs such as Oas1a, Oas1b, Irf7
and Irf1 are upregulated during infection. Although Oas1a and Irf7 were previously classified as
ISGs that could only be induced by type I IFN and ISGF3 complex (Nakaya et al., 2001), the
results of our study clearly show that these genes, as well as Oas1b and Irf1, are regulated in a
type I-IFN- and IRF-3- independent manner in WNV Eg101-infected MEFs. Either IRF-3 or
IRF-7 are needed to maintain the upregulation of these genes in infected cells but are not needed
for the initial upreguation. Although the upregulation of Oas1a, Oas1b and Irf7 is independent of
STAT1 and STAT2, the results of this study suggest that IRF-9 is required for upregulation in
WNV infected cells. To confirm that IRF-9 is the key regulatory factor, IRF-3/9-/- MEFS could
reconstituted with IRF-9 and/or IRF-3 TFs and the effect on the expression in Oas1a, Oas1b and
Irf7 after WNV infection could be analyzed. Since these genes are efficiently expressed in IRF3-/- MEFs, it would be expected that similar results are observed in IRF-3/9-/- MEFs
overexpressing IRF-9. If IRF-9 is the key regulator of Oas1a, Oas1b and Irf7 expression in
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MEFS infected with WNV Eg101, then no or low levels of expression of Oas1a, Oas1b and Irf7
should be observed in IRF-3/9-/- MEFs overexpressing IRF-3. A possible problem with this
experiment could be that the expression of IRF-3 or IRF-9 from the expression vector would be
regulated by a heterologous promoter resulting in inadequate levels of protein expression. The
best means of testing the importance of IRF-9 in upregulation of these ISGs would be by using
IRF-9-/- MEFs.

If IRF-9 is confirmed to be the key regulator of IFN- and IRF-3-independent ISG expression in
WNV Eg101-infected cells, the factors that interact with IRF-9 could be analyzed next. Although
our preliminary data showed that IRF-9 is abundant in the nucleus in WNV Eg101-infected
MEFs (data not shown), it cannot transactivate ISG expression by binding alone to an ISRE
(Kraus et al., 2003). To identify the protein(s) that interact with IRF-9 in the absence of STAT1
and STAT2 in WNV Eg101-infected cells, proteins immunoprecipitated with IRF-9 from
infected IFN alpha/beta R-/- and/or STAT2-/- cells could be analyzed by mass spectrometry. The
relevance of identified candidate TF(s) for the upregulation of ISGs in infected cells could be
then tested by RNAi knockdown or in MEFs from TF knockout mice, if available. ChIP assays
could be done to confirm that an identified TF(s) binds to ISG promoters in WNV Eg101infected IFN alpha/beta R -/- MEFs and/or STAT2-/- MEFs.

Interestingly, the upregulation of Irf1 by WNV Eg101 infection was shown not to depend on any
of the IRFs tested. In contrast, the preliminary results suggested that the p38 MAPK signaling
pathway and NF-kappa B may be involved in the regulation of Irf1 expression in infected cells.
To confirm these results the expression of Irf1 could be analyzed in infected cells stably
transfected with a p38 dominant negative construct or in p38 alpha -/- and p38 beta -/- MEFs,
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which are available. Since p38 and NF-kappa B drugs had similar effects on the upregulation of
the Oas1b and Irf1 genes by WNV Eg101 infection, it is possible that NF-kappa B is activated by
p38 in infected cells. The involvement of p38 in the activation of NF-kappa B was previously
reported (Maulik et al., 1998; Vanden Berghe et al., 1998; Liang and Gardner, 1999; Saha et al.,
2007). Unpublished data from our lab showed that NF-kappa B is activated in WNV Eg101infected MEFs. Whether WNV Eg101 infection activates NF-kappa B in p38 alpha -/- and p38
beta -/- MEFs could be tested. To directly determine whether NF-kappa B is involved in
regulation of Irf1 in cells infected with WNV Eg101, gene expression could be analyzed in mock
and WNV-infected IKK alpha-/- and IKKbeta-/- MEFs to determine whether the non-canonical
or classical NF-kappaB pathway, respectively, is involved (Massa et al., 2005). If Irf-1gene
expression is reduced when the classical pathway is knocked out, the activation of Irf1 could
next be tested in c-Rel-/- MEFs to determine whether this NF-kappa B subunit is involved.
5.4

WNV Eg101-mediated translational suppression of a subset of ISGs

Another means by which viruses can suppress the induction of the antiviral state is through
blockage of the expression of antiviral proteins. The results of this and a previous study
(Scherbik et al., 2007) showed that although the transcription of a subset of antiviral genes,
including Irf1, caspase 4 and caspase 12, is efficiently upregulated at 24 and 32 h after WNV
Eg101 infection, the translation of these transcripts is suppressed. The results of this study show
that low IRF-1 protein levels are not due to a virus infection induced increase in proteasomal
degradation and also are not due to alternative splicing. Similar results were also observed for
caspase 4 and and caspase 12 (data not shown). However, preliminary results in cells with dicer
knocked down by transient transfection of specific siRNAs suggested that IRF-1 translation may
be regulated to some extent by miRNAs. However, since complete knock down of a protein
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cannot be achieved with RNAi, additional studies are needed. To confirm the results,
dicer(+/Lox-P) and dicer(Lox-P/Lox-P) cells will be treated with 50 nM 4-hydroxytamoxifen (4OHT) to induce recombination and deplete dicer (Tan et al., 2009). Preliminary microarray
analyses done by our lab showed that miR-483 and miR-1895 expression was downregulated in
IFN beta-treated cells but upregulated WNV-infected MEFs (data not shown) suggesting that
these miRNAs could potentially be involved in the regulation of IRF-1 protein expression.
However, according to the miRDB.org database, neither of these miRNAs target Irf1 or caspase
4 or caspase 11. The miRNA microarray data and the bioinformatics predictions suggest that if
miRNAs are involved in transaltional suppression of these ISGs, they are involved indirectly
through targeting proteins involved in regulating IRF-1 translation.
Analysis of the Irf1 3'UTR with the ARE database search program revealed the presence of
AREs and supported the possibility that this type of regulation occurs in WNV Eg101-infected
cells. Cell proteins binding to ARE containing regions of the Irf1 3 'UTR could be analyzed by
EMSA and UV-induced crosslinking assays done with cytoplasmic extracts from WNV Eg101
IFN alpha/beta R-/- MEFs. If no binding is observed with the ARE regions, other regions of the
3’UTRs could be subsequently tested. An RNA affinity column could be used to enrich for
proteins interacting with labeled RNA. The eluted proteins could be separated by SDS-PAGE
and identified by mass spectrometry. Candidate proteins could be then analyzed for functional
relevance by RNAi.
SIGNIFICANCE
Overall the results of this study add to the understanding of virus-host cell interactions. Analysis
of the strategies utilized by host cells to overcome virus-induced suppression of antiviral protein
expression furthers the general understanding of WNV-host interactions and provides evidence
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about alternative signaling pathways. This study also increases general knowledge about the
diverse strategies that viruses have evolved to evade host cell antiviral responses. Further study
of these mechanisms will provide more detailed insights about the alternative mechanisms that
regulate gene transcription in infected cells and facilitate establishment of an effective antiviral
state. The importance of this study is based on the fact that many flaviviruses, such as JEV,
TBEV and dengue virus cause significant human morbidity and mortality in many geographic
regions of the world. Because there are no effective antiviral therapies, the cost of medical care
provided for individuals that develop severe disease is high. The information gained from this
study is expected to ultimately aid in the development of antiviral strategies that target WNV and
possibly other flaviviruses.
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